

















Novel markers and targets  
of collective tumor cell invasion before and after 
anti-angiogenic therapies 
 











Aquesta tesi doctoral està subjecta a la llicència Reconeixement- NoComercial – 
CompartirIgual  4.0. Espanya de Creative Commons. 
 
Esta tesis doctoral está sujeta a la licencia  Reconocimiento - NoComercial – CompartirIgual  
4.0.  España de Creative Commons. 
 
This doctoral thesis is licensed under the Creative Commons Attribution-NonCommercial-








UNIVERSITAT DE BARCELONA 
FACULTAT DE FARMÀCIA I CIÈNCIES DE L’ALIMENTACIÓ 
PROGRAMA DE DOCTORAT EN BIOMEDICINA 
 
 
NOVEL MARKERS AND TARGETS OF 
COLLECTIVE TUMOR CELL INVASION 





















UNIVERSITAT DE BARCELONA 
FACULTAT DE FARMÀCIA I CIÈNCIES DE L’ALIMENTACIÓ 
PROGRAMA DE DOCTORAT EN BIOMEDICINA 
 
NOVEL MARKERS AND TARGETS OF 
COLLECTIVE TUMOR CELL INVASION BEFORE AND AFTER 
ANTI-ANGIOGENIC THERAPIES 
 
JÚLIA SALLABERRY PINTO 
2019 
Memòria presentada per Júlia Sallaberry Pinto   
per optar al grau de Doctora per la Universitat de Barcelona 
 
 
Dr. Oriol Casanovas Casanovas          Dr. Francesc Vinyals Canals     Júlia Sallaberry Pinto 
Director                 Tutor                Autora

                                                                                                                     Table of contents 
 
1 
TABLE OF CONTENTS 
 
TABLE OF CONTENTS ............................................................................................... 1 
LIST OF ABREVIATIONS ............................................................................................ 5 
LIST OF FIGURES ..................................................................................................... 11 
LIST OF TABLES ....................................................................................................... 15 
SUMMARY ................................................................................................................. 17 
RESUMEN .................................................................................................................. 21 
INTRODUCTION ........................................................................................................ 25 
1. Metastasis cascade............................................................................................ 27 
2. Local invasion .................................................................................................... 28 
2.1 Cancer cell migration ...................................................................................................... 31 
2.1.1 Individual migration ............................................................................................... 33 
2.1.2 Collective migration .............................................................................................. 37 
3. Claudin family .................................................................................................... 43 
3.1 Structure function of claudins ......................................................................................... 43 
3.2 Claudin family and its role in cancer ............................................................................... 46 
4. Pancreatic neuroendocrine tumors .................................................................. 48 
5. RIP1-Tag2 as a pancreatic neuroendocrine tumor mouse model .................. 51 
6. Anti-angiogenic therapies ................................................................................. 53 
6.1 Effects of anti-angiogenic therapies ............................................................................... 56 
7. Previous results of the group ........................................................................... 61 
7.1 Invasion cancer cell mechanism after anti-angiogenic treatment .................................. 61 
OBJECTIVES ............................................................................................................. 65 
1. Project design .................................................................................................... 68 
MATERIALS AND METHODS ................................................................................... 71 
1. Animal procedures............................................................................................. 73 
1.1 Animal model .................................................................................................................. 73 
1.1.1 Mice genotyping .................................................................................................... 73 
1.2 Anti-angiogenic treatments ............................................................................................. 75 




1.2.1 DC101 production and purification ....................................................................... 75 
1.2.2 Determination of the antiangiogenic effects ......................................................... 76 
1.3 Determination of survival time ........................................................................................ 76 
1.4 Invasion determination ................................................................................................... 76 
1.5 Tumor and organ collection ............................................................................................ 78 
1.6 Histological studies ......................................................................................................... 78 
2. Protein analysis of tumor samples ................................................................... 79 
2.1 Immunohistochemistry .................................................................................................... 79 
2.1.1 CLDN4 and CDH1 immunohistochemistry quantification ..................................... 80 
2.2 Preparation of protein lysates from tumor tissues .......................................................... 81 
2.3 Protein quantification ...................................................................................................... 81 
2.4 Western blotting .............................................................................................................. 82 
3. Molecular analysis of tumor samples ............................................................... 84 
3.1 RNA extraction................................................................................................................ 84 
3.2 Obtention of cDNA from mRNA ...................................................................................... 85 
3.3 Real-Time Quantitative PCR (RT-qPCR) ....................................................................... 85 
4. Cell culture techniques ...................................................................................... 86 
4.1 Mycoplasma test ............................................................................................................. 87 
4.2 Cell freezing and cryopreservation ................................................................................. 87 
4.3 βTC4 spheroids .............................................................................................................. 88 
4.3.1 2,5D in vitro model ................................................................................................ 88 
4.3.2 3D in vitro model ................................................................................................... 89 
4.3.3 Spheroid harvesting procedure............................................................................. 89 
4.4 Cell treatments................................................................................................................ 90 
4.4.1 Hypoxia and nutrient deprivation .......................................................................... 90 
4.4.2 Y201636 treatment ............................................................................................... 91 
4.5 Migration assay in 2,5D model ....................................................................................... 91 
4.6 Invasion assays .............................................................................................................. 92 
4.6.1 Transwell® invasion assay ................................................................................... 92 
4.6.2 3D spheroid invasion assay .................................................................................. 92 
5. In vitro protein detection ................................................................................... 93 
5.1 Immunocytofluorescence ................................................................................................ 93 
5.1.1 2D model............................................................................................................... 93 
5.1.2 3D model............................................................................................................... 94 
5.2 Western blotting .............................................................................................................. 95 
6. In vitro molecular analysis ................................................................................ 96 
7. In silico clinical samples analysis .................................................................... 96 
                                                                                                                     Table of contents 
 
3 
8. Statistical analysis ............................................................................................. 96 
RESULTS ................................................................................................................... 99 
1. Invasion morphological delineation ............................................................... 101 
1.1 RIP1-Tag2 mouse model .............................................................................................. 101 
1.2 βTC4 in vitro 2D, 2,5D and 3D model .......................................................................... 104 
2. Invasion molecular characterization .............................................................. 116 
2.1 Characterization of CDH1-mediated collective invasion .............................................. 116 
2.2 EMT-related genes in RIP1-Tag2 tumors ..................................................................... 122 
3. Collective invasion candidates ....................................................................... 125 
3.1 Barrier claudins as collective proinvasion markers in RIP1-Tag2 tumors .................... 125 
3.2 CLDN4 expression validation in RIP1-Tag2 tumors ..................................................... 130 
3.3 Barrier claudins in βTC4 2D and 3D model in vitro model ........................................... 136 
4. CLDN1 functional in vitro validation ............................................................... 144 
4.1 CLDN1 expression in βTC4 cells exposed to hypoxia and lack of nutrients effects .... 144 
4.2 CLDN1 in vitro inhibition ............................................................................................... 148 
4.2.1 Effects of CLDN1 inhibition of βTC4 cells in 2D model ...................................... 148 
5. Clinical relevance in PanNETs patients .......................................................... 154 
5.1 EMT-related genes in patient samples ......................................................................... 155 
5.2 Expression of barrier-forming claudins in clinical samples ........................................... 157 
DISCUSSION ........................................................................................................... 161 
1. Morphological collective invasion characterization ...................................... 163 
2. Molecular collective invasion characterization .............................................. 165 
3. Collective invasion candidates ....................................................................... 166 
4. CLDN1 in vitro modulation .............................................................................. 171 
5. Clinical samples validation ............................................................................. 173 
6. Clinical relevance and future treatments ....................................................... 174 
7. Claudin binders as a novel strategy to treat cancer ...................................... 175 
CONCLUSIONS ....................................................................................................... 179 
REFERENCES ......................................................................................................... 183 
 
  
                                                                                                                  List of abbreviations 
 
5 





2,5D Two and half-dimensional 
2D  Two-dimensional 
3D Three-dimensional  
aa Aminoacids 
AAALAC Association for Assessment and Accreditation Laboratory Animal Care 
AJCC American Joint Committee on Cancer 
AMT Amoeboid-mesenchymal migration 
APS Ammonium persulfate 
BCA Bicinchoninic acid 
BM Basement membrane 
B-NHL B-cell non-Hodgkin lymphoma 
BSA Bovine serum albumin 
CDH1 E-cadherin  
cDNA Complementary DNA 



















CO2 Carbon dioxide 
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Cpm Counts per million 
CRC Colorectal cancer 
CSF-1  Type I receptor of colony stimulating factor 
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ECL1 Extracellular loop 1 
ECL2 Extracellular loop 2 
ECM Extracellular matrix 
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EMT Epithelial-mesenchymal transition 
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19 
Local invasion is a key cell-biological event in the metastatic cascade. In 
response to a changing microenvironment, cancer cells may act using two main 
strategies of invasion: single cell invasion and collective invasion.  Determining 
how tumor cells initiate and sustain local invasive Behaviour might help to improve 
patient diagnosis and lead to the development of new intervention modalities. 
Therefore, the aim of this thesis is to elucidate which molecular mechanisms are 
involved in PanNETs invasion before and after anti-angiogenic therapies. 
Results from our group have demonstrated an irreversible increase in the 
incidence of invasive tumors during anti-angiogenic treatment in the RIP1-Tag2 
mouse model. The RIP1-Tag2 mouse model is a valuable prototype of stepwise 
progression of tumorigenesis, and for this reason represents an appropriate 
choice for studying invasion in PanNETs. In addition, three dimensional models 
were developed with the aim of verifying the collective cell invasion process in 
βTC4 spheroids from RIP1-Tag2 tumors. 
First, the morphology of RIP1-Tag2 tumors was described as collective 
tumor cell invasion, both before and after anti-angiogenic treatment. In detail, 
CLDN4 expression was associated with a high invasion capacity, reflected in the 
barrier function stability and adhesion union between cells. Cells and spheroid 
βTC4 models, in turn, demonstrated the functional implication of CLDN1 in the 
invasion of cancer cells. Finally, in clinical samples of PanNETs patients, CLDN1 
was directly associated with tumor progression.    
In summary, we identified a new link between barrier claudins, specifically 
1 and 4, and the collective cell invasion process. In the future, through further 
validations, these markers could be used as tumor progression biomarkers for 
















































La invasión local es un evento biológico celular clave en la cascada 
metastásica. En respuesta al microambiente tumoral, las células pueden actuar 
utilizando dos estrategias principales de invasión: la invasión de células 
individuales y la invasión colectiva. Determinar cómo las células tumorales inician 
y mantienen el comportamiento invasivo local podría contribuir en la mejora del 
diagnóstico del paciente y conducir al desarrollo de nuevas modalidades de 
intervención. Por lo tanto, el objetivo de esta tesis es determinar cuáles son los 
mecanismos moleculares involucrados en la invasión de PanNETs antes y 
después de las terapias anti angiogénicas.  
Resultados previos de nuestro grupo demostraron un aumento irreversible 
en la incidencia de tumores invasivos durante el tratamiento anti angiogénico en 
RIP1-Tag2.  Los ratones transgénicos RIP1-Tag2 son un prototipo detallado de 
la progresión gradual en la tumorigénesis, por ello representan un modelo animal 
ideal para estudiar el proceso de invasión in vivo. Además, se desarrollaron 
modelos tridimensionales buscando verificar el proceso de invasión colectiva en 
esferoides βTC4 derivados de tumores RIP1-Tag2. 
En primer lugar, la morfología de los tumores RIP1-Tag2 se ha descrito 
como colectiva tanto antes y como después de la inhibición farmacológica de la 
angiogénesis. En detalle, la expresión de CLDN4 ha sido asociada a la capacidad 
de invasión colectiva, reflejada en la estabilidad de la función barrera y la 
integridad de la adhesión entre las células. Las células y esferoides βTC4, por su 
parte han demostrado la implicación funcional de CLDN1 en la invasión de 
células cancerosas. Finalmente, una asociación directa entre la expresión de 
CLDN1 y la progresión tumoral ha sido observada en las muestras clínicas de 
pacientes PanNETs. 
En resumen, hemos descrito una nueva conexión entre las claudinas de 
barrera, especialmente las CLDN1/4 y el movimiento colectivo de invasión 
tumoral. En el futuro, a través de validaciones adicionales, estos marcadores 
podrían ser aplicados como biomarcadores de progresión tumoral de PanNETs, 
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1. Metastasis cascade 
According to the World Health Organization (WHO), cancer represents the 
second leading cause of mortality globally, and was cause for an estimated 9.6 
million deaths in 2018. Nowadays, about 1 in 6 deaths is due to cancer. 
Metastasis is a hallmark of cancer, being responsible for as much as 90% of 
cancer-associated mortality (World Health Organization, 2018). 
A complex sequence of cell-biological events are involved in the metastatic 
spread of cancer cells from primary tumors to distant parts of the body. During 
metastasis cascade, epithelial cells from primary tumors undergo the following 
steps: (1) invasion of surrounding tissue through extracellular matrix (ECM) and 
stromal cell layers (local invasion), (2) penetration into microvasculature of the 
blood vessels and lymph (intravasation), (3) survival in rigorous conditions of 
translocation through the bloodstream to microvessels into the parenchyma of 
distant tissue (survival in the circulation), (4) extravasation from the bloodstream 
(extravasation) (5) adaptation to foreign microenvironment of distant tissues, 
facilitating cell proliferation and micrometastases formation, and (6) finally once 
in metastatic sites, activation of their proliferative program to promote 
macroscopic, clinically detectable neoplastic growths (metastatic colonization) 
(Figure 1) (C. Chaffer and Weinberg 2011; Valastyan & Weinberg 2011). 




Figure 1. Steps of metastasis cascade. Tumor cells locally invade the surrounding tissue, enter and 
survive in microvasculature during the translocation to distant tissues, and finally adapt to the foreign 
microenvironment and colonize a second distant organ forming metastasis.  Extracted from (Valastyan 
& Weinberg 2011). 
2. Local invasion  
Local invasion is an essential step of the metastatic cascade, given that, 
without it, none of the following metastatic steps may occur. In this sense, tumor 
microenvironment modifications play an important role in initiating the cell 
invasion process. 
The basement membrane (BM) is a layer of specialized ECM composed of 
several glycoproteins and proteoglycans. Normally, the BM membrane supports 
the structure on which epithelial and endothelial cell layers grow, thus acting in 
epithelial tissue organization. The BM acts by preventing invasion into the 
subjacent stroma of tumors at early stages. Nevertheless, in malignant tumors, 
cancer cells disrupt regulatory mechanisms and induce proteolytic activities on 
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the BM and the interstitial ECM, favoring the cell invasion process (Lu, Weaver, 
and Werb 2012; Valastyan & Weinberg 2011). 
In this way, at the ‘carcinoma in situ’ stage, cancer cells are still 
encapsulated by the BM and during local invasion cancer cells must first cross 
the BM. Due to BM degradation, the stroma becomes reactive with the cross-talk 
between tumor cells and stromal cells. Reactive stroma is characterized by an 
increased presence of immune cells and fibroblasts, which can help to deposit 
ECM and reorganize the stromal network. Consequently, stromal network fibers 
which before were well organized appear ‘curly’ and later increase in density and 
stiffness. In addition, the mixing of cancer and stroma cell types may further the 
disorganization of the tissue. Therefore, cancer cells from invasive tumors take 
advantage of a dysfunctional BM to migrate locally and invade toward the blood 
stream (Figure 2) (Clark and Vignjevic 2015). Thus, reciprocally, tumor cells 
influence the stroma and vice versa, together driving cancer progression (Peter 
Friedl and Alexander 2011). 
 
Figure 2. Tumor invasion microenvironment. Sequential microenvironment alterations that 
influence tumors cells and vice versa. Extracted from (Clark and Vignjevic 2015).





Despite the fact that tumor biologists have identified different mechanisms 
involved in malignant cell invasion, the attempts to define limiting mechanisms 
that govern invasive and metastatic cancer cell migration have largely failed.  This 
is due to the fact that cancer cell invasion is a heterogeneous and adaptive 
process depending mainly on microenvironmental and diverse structural and 
molecular conditions (Peter Friedl and Alexander 2011). According to the cell type 
and tissue environment, cells may migrate using two major strategies— 
individually, when cell-cell junctions are absent, or, in solid cell strands, sheets, 
files or clusters, called ‘collective migration’, when cell-cell adhesions are 
maintained (Figure 3) (Peter Friedl and Wolf 2010). 
Single cell and collective migration strategies are simultaneously present 
in many tumors. While leukemias, lymphomas and most solid stromal tumors such 
as sarcomas disseminate via individual cells, epithelial tumors commonly migrate 
by collective mechanisms. Generally, the lower the cell differentiation stage, the 
more likely the tumor is to migrate via single cell. Logically, the molecular 
repertoire in each migratory strategy is different according to the different 
movement pattern (Peter Friedl and Wolf 2003). 
 
Figure 3. Individual cells and collective migration strategy. Variations of cell migration method 
and the most incident tumors of each type.  Cell drawings have been extracted from (Van Helvert, 
Storm, and Friedl 2018). 
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2.1 Cancer cell migration  
Many years ago the full EMT was considered crucial for cell movement, as 
it was believed that only cells with a mesenchymal phenotype, rather than 
epithelial cells, were able to migrate. Nonetheless, EMT has since been described 
as a process of intermediary phases, ranging from full EMT to partial, or even 
subtle states of EMT with very irregular Behaviours as to migration type and cell 
mobility (C. L. Chaffer et al. 2016). Nowadays, well-established examples of 
collective cell migration and invasion are known in many types of human 
malignant tumors (Wang et al. 2016). 
Specifically, if monitored in a time-resolved manner, invasion programs are 
a continuous range of stages rather than discrete states, from stringently 
collective, to partial to complete but temporary individualization. The mechanisms 
of cell migration and invasion are plastic and allow the rapid adaptation to 
environmental changes and challenges; these adaptations often result in 
transitions between different modes of migration (Peter Friedl and Wolf 2010; 
Sanz-Moreno and Marshall 2010). Such plasticity likely originates in response to 
changing microenvironmental conditions and to therapeutic challenge. Further, 
the diversity of invasion is promoted by the rewiring of signaling networks and cell 
survival during therapy and tissue damage (Peter Friedl and Alexander 2011). 
In particular, it has been identified that ECM parameters such as stiffness 
or density are able to regulate the transition between amoeboid-mesenchymal 
migration (AMT) and mesenchymal-ameboid transition (MAT) (Figure 5B-CD), 
which is a dynamic process in which cells display properties of both migratory 
phenotypes (Talkenberger et al. 2017).  This same plasticity between different 
invasion states occurs in epithelial–mesenchymal transition (EMT), and in the 
mesenchymal–epithelial transition (MET) process (Figure 4A-B) (Peter Friedl 
and Gilmour 2009). 
 





Figure 4. Plasticity among invasion and migration transition strategies. (A) Collective migration. 
(B) Mesenchymal migration. (C) Amoeboid blebby migration. (D) Amoeboid filopodal migration. Cell 
drawings have been extracted from (Van Helvert, Storm, and Friedl 2018).  
Briefly, taking into account mainly migration features, the movement 
strategies are divided into: (i) collective cell migration, characterized by high levels 
of proteins responsible for cell adhesion, ECM degradation and union; the 
invasive cells from collective mode may undergo EMT transition (Figure 4A). (ii) 
mesenchymal migration, in which cells maintain ECM contact and degradation, 
and are thus able to pass by MAT and MET transition (Figure 4B), (iii) amoeboid 
migration, which is also distinguished by cellular adhesion to the substrate, in 
which 'amoeboid filopodal' cells maintain bonds to ECM, whereas 'ameboid 
blebby' cells not, these cells may suffer AMT transition (Figure 4C-D). 
The role of each strategy of invasion will be further discussed in the 
following sections of this thesis. 
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2.1.1 Individual migration  
Nowadays two types of individual migrating tumor cells are recognized: 
mesenchymal (fibroblast-like) and amoeboid. 
 Amoeboid/ Rounded 
The term ‘amoeboid migration’ refers to the fact that amoeba Dictyostelium 
discoideum are known to migrate by this mechanism.  During amoeboid 
movement, cells are characterized by migrating with low adhesion force, adopting 
spherical shapes or high contractility mediated by actomyosin. (P Friedl, 
Borgmann, and Bröcker 2001). Amoeboid tumors are frequently derived from 
hematopoietic or neuro-ectodermal tissue, including leukemias, lymphomas, and 
small cell lung carcinoma. Nonetheless, amoeboid movements are also found in 
cell subgroups of most other tumor types (Peter Friedl and Alexander 2011). 
Amoeboid migration characteristics allow rapid adaptation to a given 
environment, as cells are highly deformable, their adhesion to the ECM is 
relatively weak, and proteolytic action is reduced or absent. Cells develop high 
migration velocities due to low adhesion among other cells, moving faster than 
cells in mesenchymal migration mode (Talkenberger et al. 2017). These migration 
characteristics allow rapid adaptation to a given environment, development of 
high migration velocities, and contact with other cells in a dynamic yet reversible 
manner (P Friedl, Borgmann, and Bröcker 2001). 
The morphological shape, type of cell protrusions and cytoskeletal flexibility 
are regulated by two GTPase proteins RhoA and Rac. Cell direction, determined 
by polarization and retraction, are controlled by cortical actomyosin contractility 
which is regulated by RhoA via Rho kinase (ROCK) signaling and myosin II 
activity (Boekhorst and Friedl, 2016). 
However, amoeboid movement may be classified according to cellular 
adhesion to the substrate. Blebby ameboid migration is mediated by contractile 
Rho-directed actomyosin and lacks defined adhesions, cell translocation is 
mediated by propulsion using either blebs or lateral intercalation (Figure 6C). 




Filopodal ameboid migration already uses Rac-dependent filopodia (Figure 6D). 
Thus, cells present small or diffusely organized adhesion sites that generate weak 
to negligible adhesion force toward the substrate (Lorentzen et al., 2011; 
Poincloux et al., 2011; Boekhorst and Friedl, 2016). 
In particular, amoeboid cells follow the trend of migrating in the absence of 
proteolytic ECM breakdown, in this sense cancer cells use actomyosin-based 
mechanical forces to physically displace matrix fibrils. In fact, clinical trials that 
demonstrated MMP inhibitors failure to prevent cancer progression confirm this 
hypothesis and suggests protease-independent mechanisms of invasion as a 
potential mechanism relevant in vivo (Peter Friedl and Alexander 2011; Sabeh, 
Shimizu-Hirota, and Weiss 2009). 
 Mesenchymal 
The mesenchymal migration mode is often observed in sarcomas, gliomas, 
and epithelial cancer cells after undergoing epithelial-to-mesenchymal transition 
(EMT) (Chanrion et al. 2014).  The EMT process represents a cell biological 
program that concomitantly suppresses epithelial markers whereas upregulating 
mesenchymal ones (C. L. Chaffer et al. 2016). Briefly, mesenchymal tumor cells 
often express EMT markers, including inducing transcription factors (EMT-TFs) 
Oct-4, Twist, Snail/Slug, Zeb1/2 and cytoplasmic vimentin, which allow their 
detection in tissue samples in infiltrating remodeled tissue (Figure 5) (A. Smith, 
Teknos, and Pan 2013; Zeisberg and Neilson 2009; Lamouille, Xu, and Derynck 
2014). 




Figure 5. Roles of major EMT transcription factors. Epithelial–mesenchymal transition (EMT) is 
driven by SNAIL, zinc-finger E-box-binding (ZEB) and basic helix–loop–helix (bHLH) transcription 
factors that repress epithelial marker genes and activate genes associated with the mesenchymal 
phenotype. Extracted from (Lamouille, Xu, and Derynck 2014). 
In particular, EMT-TF genes when combined and activated may confer an 
increase of migratory and invasive capacity on cells, facilitating, in consequence, 
EMT-responsive cells movement out of primary tumor sites and into the 
circulation, thereby enabling their metastatic potential (Figure 6). In relation, 
tumor microenvironment influence on the epithelial cancer cells is intermediated 
via heterotypic cell-cell signaling molecules, among which are Wnt, TGFβ and 
Notch. Overall, as research increases and the connections between EMT and 
carcinomas are elucidated, the signaling player numbers implicated in driving the 
EMT keeps growing (C. L. Chaffer et al. 2016). 
In relation to canonical molecules contribution to EMT process, a wide 
range of growth factors including the epidermal growth factor (EGF), insulin 
growth factor (IGF), hepatocyte growth factor (HGF), fibroblast growth factor 
(FGF) and platelet-derived growth factor (PDGF) have also been described as an 




EMT program trigger. As well as hypoxia-inducible signals involving the 
transcription factor HIF1-α, as well as, inflammatory signals (NF-κB) and 
cytokines, such as interleukin-1β (IL-1β) and the tumour necrosis factor alpha 
(TNFα), showed to cooperate in the complex network of signals involved with EMT 
activation within carcinoma cells (Lamouille, Xu, and Derynck 2014; B. Smith and 
Bhowmick 2016). 
 
Figure 6. States of EMT phenotypes in cancer.  The mesenchymal tumor cell morphology is 
determined by an elongated cell shape with an oval nuclear and a protruding pseudopod and/or 
multiple filopods, which are responsible for determining the direction of migration by adherence to and 
pull on ECM substrate. In the cell edge, Rac-induced actin assembly and integrin binding to the 
substrate induce cell polarization and protrusion. At the same time as integrin, also FAK and Src 
kinases induce maturation of focal ECM adhesion, determining thus a contractile tension and pulling 
forces toward ECM structures. On the other hand,  at the rear,  actomyosin contractility induced by 
RhoA reduces anchorage of the cell rear  and leads to forward sliding of the cell body(Boekhorst and 
Friedl, 2016). 
The mesenchymal tumor cell morphology is determined by an elongated 
cell shape with an oval nuclear and a protruding pseudopod and/or multiple 
filopods, which are responsible for determining the direction of migration by 
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adherence to and pull on ECM substrate. In the cell edge, Rac-induced actin 
assembly and integrin binding to the substrate induce cell polarization and 
protrusion. At the same time as integrin, also FAK and Src kinases induce 
maturation of focal ECM adhesion, determining thus a contractile tension and 
pulling forces toward ECM structures. On the other hand,  at the rear,  actomyosin 
contractility induced by RhoA reduces anchorage of the cell rear  and leads to 
forward sliding of the cell body (Boekhorst and Friedl, 2016). 
Therefore, Rac-mediated cell elongation at the leading edge and Rho-
induced rear contraction allows cycles of cell-matrix adhesion, pulling and 
relaxation on cell structure, thus, promoting cell movement. In addition, 
concomitant with this process, surface matrix metalloproteases (MMPs) remove 
ECM structures and barriers, promoting tissue remodeling and generating a tissue 
along the spatially widened migration path (Figure 4B) (Boekhorst and Friedl, 
2016). 
2.1.2 Collective migration  
In the ecosystem innumerable birds, fish, arthropods and land animals live 
and migrate in groups. This Behaviour is a manner that protects them and 
increases the probability of reaching their final destination. Similarly, coordinated 
cohesive groups or nests are formed to migrate toward their destination during 
multicellular organisms development and the progression of human diseases 
(Peter Friedl and Mayor 2017). In this way, the collective migration is determined 
by three main cell Behaviours (Peter Friedl and Gilmour 2009): 
i)       Cells remain physically and functionally connected such that the 
cohesion of cell–cell junctions is maintained during movement. 
ii)       Traction and protrusion force for migration and maintain cell–cell 
junctions is determined by multicellular polarity and 'supracellular' organization of 
the actin cytoskeleton. 




iii)     Moving cell groups change the tissue along the migration path, either 
by clearing the track or by causing secondary ECM modifications. 
The neural crest cells and neuroblasts migrate in an organized manner and 
retain intercellular adhesion to go through long distances and form discrete 
tissues and organs. Angiogenic events also showed cells migrating in groups 
during retina development and inflammatory diseases (Figure 7A) (Wang et al. 
2016).  In cancer, it has been described that collective invasion is an important 
strategy for local tissue infiltration, as well as metastatic evasion in epithelial 
tumors such as breast cancer, squamous cell carcinoma, pancreatic cancer, 
colon cancer, and others (Figure 7B), as well as, in mesenchymal tumors (Peter 
Friedl and Mayor 2017). 
Collectivity of migrating cancer cells shows innumerable advantages for 
surviving the metastatic cascade in comparison to individual-cell migration, 
including: (i) a highly promigratory and prosurvival environment between 
connected cells by secretion of growth factors, chemokines and proteases; (ii) the 
passive displacement of otherwise poorly mobile or even immobile but highly 
proliferative cells inside the strands by highly mobile neighbor or leader cells; and 
(iii) safety of cells located in inner regions of groups, such as reduced immune 
cell attack or lower shear stress and nuclear damage in the tissue or vasculature 
(Boekhorst and Friedl, 2016). 
 
Figure 7. Collective cell migration verified in the body development and human cancer. (A) 
Developing adrenal gland in 13-week human embryo, showing the groups of neural crest-derived 
cells. Hematoxylin and eosin stain. (B) Representative images for different human cancers: (a) 
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adenocarcinoma in the pancreas, (b) adenocarcinoma in the colon, (c) sebaceous carcinoma in the 
skin. Image has been adapted from (Wang et al. 2016). 
Overall, collective movement may vary depending on the context. Thus, 
collective cell movement can happen across a tissue surface by two-dimensional 
migration monolayers, when cells move across tissues to form a single-layered or 
multilayered epithelium (Figure 8A) or by multicellular strands through a three-
dimensional tissue scaffold (Figure 8B–F). In this case, multicellular 3D strands 
cells can generate of an inner lumen (and therefore a tube structure), such as in 
gland formation (Figure 8B) or vascular sprouting during angiogenesis (Figure 
8C), or they may move as mass poorly organized (strands), such as in invasive 
cancer (Figure 8D). Also, isolated groups can move through tissue if they detach 
from their origins; such as border cells in the Drosophila melanogaster egg 
chamber (Figure 8E) and metastatic cancer cell clusters that penetrate the tissue 
stroma (Figure 8F) (Peter Friedl and Gilmour 2009). 





Figure 8. Patterns of collective cell migration depending on the context. (A) two-dimensional 
migration monolayers (B-F) multicellular strands migration through a three-dimensional tissue 
scaffold. Extracted from (Peter Friedl and Gilmour 2009). 
In the context of cancer cell invasion, all types of collective movements may 
be adopted by tumor cells. According to histological samples from both patient 
lesions and mouse models in vivo, it was verified that collective invasion patterns 
present a striking morphological and molecular variability depending on tumor 
type and the tissue that is invaded (Boekhorst and Friedl, 2016; Friedl and Mayor, 
2017). 
Mechanically, cell-cell contacts coordinate and polarize collective migratory 
cells into a multicellular functional single system (Peter Friedl et al. 2012). 
Different levels of actin dynamics, substrate interaction and remodeling of ECM 
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define leader and follower cell Behaviours. At the invasive front, leader cells 
through Rac-guided filopodia protrusions and integrin-mediated substrate 
adhesion connect with surrounding tissue structures (Yamaguchi et al. 2015). Rho 
molecule has highest activity towards the cell front, generating actomyosin-
mediated contractility and pulling force between the substrate and follower cells. 
In this context specially, follower cells depend on stable cell-cell adhesion to 
withstand the drag forces generated by the leader cells and Rho-mediated actin 
contraction. cell-cell junctions are maintained by cadherins (especially by E-
cadherin in epithelial tumors) and their connection with cortical actin mediates the 
stability of the adherent junctions. Also, proteolytic remodeling of the matrix, 
particularly through MMPs, to generate a path of least resistance over from which 
the cells advance (Figure 9D) (Haeger et al., 2014; Boekhorst and Friedl, 2016) 
 Other cell-cell adhesion systems include members of the immunoglobulin 
superfamily and adhesions of ephrins/EpH receptors that mediate slower or 
transient cell-cell interactions, as well as connexins, which allow communication 
through communicating junctions and signal transduction between connected 
tumor cells (Boekhorst and Friedl, 2016). Finally, it is important to emphasize that 
proteins responsible for coordinating the collective movement are still poorly 
understood, changing depending on the type of cancer tissue and the overall 
contexts. Furthermore, neither is it clear yet whether leading cells exist in all types 
of cancers or not (Wang et al. 2016). 
 Collective migration/invasion models 
Studying collective invasion in vitro 
2D assays: Scratch/wound assays analyse cell migration across a flat 
surface. Benefits involve the technical simplicity and suitability for large-scale 
assays. As disadvantages are restriction to 2D substrates. Time-lapse imaging 
may evaluate cell-cell junction stability, cell–neighbor relationships and traction-
force generation (Peter Friedl et al. 2012). 




3D ECM-based assays/3D ECM spheroid invasion assay: Multicellular 
clusters or aggregates seeded into 3D ECM (such as collagen I or Matrigel®), 
with or without presence of another type of cell, favoring radial invasion of 
individual cells and multicellular strands. Aggregate size and shape, and cell–cell  
adhesion junction immunostaining, may differentiate between individual and 
collective invasion. The level of collective and individual cell invasion is measured 
through number of invasive strands or cell and vertical penetration depth (Peter 
Friedl et al. 2012). 
Studying collective invasion in vivo 
Animal models: Studies can be performed in mice that develop tumors 
spontaneously, or with heterotopic and orthotopic tumor implants. Mutant mice 
mimic natural tumor progression, but their unpredictable progression requires 
careful early stage tracking. Heterotopic sites are ideal for direct imaging, whereas 
orthotopic injection into the tissue of origin most accurately recapitulates the tumor 
microenvironment  (Peter Friedl et al. 2012). 
Histological studies: Typical histological and immunohistochemical 
analysis should determine the extent of invasion, whether invading cells are 
cohesive maintaining intact cell–cell junctions, and the connection with human 
pathology information  (Peter Friedl et al. 2012). 
Intravital imaging: Intravital microscopy of tumor cells may characterize the 
type of invasion (collective and individual), their speed and localization In addition, 
time-lapse 3D monitoring of cell dynamics can provide cellular and subcellular 
resolution to characterize both single-cell and collective invasion. 
Multiple imaging session studies: The transparent imaging windows are 
recommended for serial imaging of a tumor area to long-term for days or weeks. 
This method allows an accurate assessment of slow cell and tissue dynamics, 
including collective invasion and tumor growth  (Peter Friedl et al. 2012). 
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Challenges of in vivo imaging: Some technical problems that can confound 
collective invasion analysis such as passive drift of cells or tissue regions, tissue 
compaction or artefacts due to surgery. These difficulties may be overcome by 
optimizing sample positioning through custom tissue holders; using long-term 
window chambers to prevent impact on the tissue structure before or during 
imaging; monitoring collective invasion over days and weeks  (Peter Friedl et al. 
2012). 
3. Claudin family  
3.1 Structure function of claudins 
Claudins are part of tight junctions (TJs) adhesion complexes, in which 
plasma membranes of neighbor cells become closely united, forming an 
impermeable barrier between cells within the tissue (Figure 11A) (Peter Friedl and 
Mayor 2017). There are thought to be around 26 human claudins with 
physiological role. Claudins have between 207 and 305 amino acids and  possess 
molecular masses of 21–34 kDa (Günzel and Yu 2013). 
General structure of claudins is determined by an intracellular NH2 
terminus together with a longer intracellular COOH terminus, two extracellular 
loops (ECL1, which is larger, and a smaller ECL2), and one short intracellular loop 
(Günzel and Yu 2013). The larger first loop is responsible for specific paracellular 
tightening ion permeability, whereas the shorter second extracellular loop seems 
determinant to adhesive function between the opposing cell membranes (Figure 
10B) (Scarpa et al. 2017; Günzel and Yu 2013; Markov, Aschenbach, and 
Amasheh 2015). 
In addition, the claudin family possesses a COOH-terminal PDZ-binding 
motif, through which the majority of claudins, are able to connect with PDZ 
domains from scaffolding/adapter proteins such as ZO1, ZO2, ZO3. In turn, this 
interaction also control a several signaling pathways involved in actin 
organization, cell polarity, as well as transcriptional regulation (González-Mariscal 
et al. 2014). 




As to interactions between the claudins within one tight junction which can 
be considered: homo- and heteromeric interactions that may happen in cis or in 
trans. Recent evidence demonstrated that claudin-1 is able to trans-interact with 
-3, but not with claudin-2 or claudin-4. However, the claudins ability to trans-

















Figure 9. Claudins structure and function. (A) Location of TJs between epithelial cells and 
schematic drawing of a TJ membrane. (B) Secondary structure of claudin protein (C) Crystal structure 
of Cldn15 (D) Interaction possibilities between claudins such as, reported for claudin-1 and -3. Images 
have been adapted from (Günzel and Yu 2013; Gerd Krause et al. 2008; G. Krause, Protze, and 
Piontek 2015; Tamura and Tsukita 2014). 
A general property of claudins in the TJ is the paracellular sealing function, 
which is tissue-, size- and charge-selective. Thus, it was defined that claudins 
operate predominantly as barriers or pores that are selective to cations and ions. 
Barrier forming claudins are those claudins that increase in transepithelial 
resistance (TER) sealing the cells, whereas pore-forming claudins decrease TER, 
increasing paracellular permeability (Günzel and Yu 2013; Gerd Krause et al. 
2008).  Claudins that unequivocally are qualified as pore-forming claudins are: 
claudin-2, -10b, and -15 as cation pores and claudin-10a and -17 as anion pores, 
being that claudin-2 acts as the only paracellular water channel known until now. 
The barrier-forming claudins that decrease a permeability to cations are: claudin-
1, -3, -4, -5, -6, -8, -9, -11, -14, -18, and, finally claudin-19 acts decreasing 
permeability to anions (Günzel and Yu 2013; Gerd Krause et al. 2008; Tamura 
and Tsukita 2014; Markov, Aschenbach, and Amasheh 2015; Rosenthal et al. 
2017). 
3.2 Claudin family and its role in cancer 
Accumulated data has demonstrated that some claudins expression are 
decreased or increased in human tumors in a tissue-specific mode, indicating a 
possible specific mechanism in targeting cells during carcinogenesis (Figure 10). 
Specifically, claudin expression alterations have been shown to be significantly 
correlated with different steps of prognosis, such as patient survival and 
recurrence in some cancers, suggesting the claudin family as prognostic markers 
in some cancers (Osanai et al. 2017). 




Figure 10. Claudin expression dysregulated in cancers from various organs. Image has been 
adapted from (Osanai et al. 2017). 
In detail, as to collective invasion, until now among all claudin family 
components, only claudin-1 was related to collective migration/invasion in in vitro 
studies. According to these results, claudin-1 is a key protein that facilitates the 
collective invasion in mammary and cervical carcinoma cells (Fortier, Asselin, and 
Cadrin 2013; Giampieri et al. 2009). In the case of rat mammary cells, single cell 
migration was found under high TGFβ expression, leading to metastases. 
Nonetheless, with TGFβ inhibition, high claudin-1 expression levels were verified 
and, led to cancer cells moving collectively, resulting in the lymphatic invasion of 
these cells (Giampieri et al. 2009). In addition, in cervical carcinoma cells, once 
again, the capacity of claudin-1 to induce collective migration was demonstrated.  
This time, as a consequence of knockdown of keratin (K8/18), higher collective 
migration was shown and invasion capacity of the tumor cells through claudin-1 
protein and independently of EMT markers. Through this knowledge, it was 




suggested that claudin-1 increases cell cohesion and consequently, facilites and 
promotes the collective cell migration (Fortier, Asselin, and Cadrin 2013). 
4. Pancreatic neuroendocrine tumors  
Neuroendocrine tumors (NETs) are epithelial tumors with essentially 
neuroendocrine differentiation which have the same phenotype in common. 
Although at different levels, these tumors have propensity to metastasize to the 
liver, independently of the primary tumor origin (Lewis et al., 2017). It has been 
calculated that the incidence of NETs could represent 7 cases per 100,000 
people. In fact, this rate significantly increased in recent years, being in part a 
relative true increase in incidence, and, on the other hand, this increase may 
reflect better detection and improved diagnosis observed in the recent years (Yao 
et al. 2008). 
Pancreatic neuroendocrine tumors (PanNETs) form in hormone-making 
cells (islet cells) of the pancreas. The PanNETs annual incidence has 
approximately 1 per 100,000 individuals per year (Figure 11), thus, representing 
the second most common epithelial neoplasm from pancreas. Further, these 
tumors show a discouraging mortality rate of 60% of diagnosed cases (Lewis et 
al., 2017) 




Figure 11. Incidence of PanNETS annually in the period from 1973 to 2013. PanNETs incidence 
by year of diagnosis. Extracted from  (Lewis et al., 2017). 
The classification for PanNETs was performed to organize tumors 
according to their associated-function to hormones secretion in two groups: non-
functional and functional types. Among functional and secreting tumors are 
insulinoma, glucagonoma, and others. Already, non-functional PanNETs do not 
result in syndromes of hormonal excess, but, on the other hand, invade normal 
tissue and metastasize causing higher mortality rates (Ehehalt et al. 2009). It is 
known that most PanNETs are non-functional, and 85% will develop metastases 
during their life (Lawrence et al. 2011). Overall, metastasis in PanNETs 
independently of functional classification, represent 4 years less mean duration in 
survival in relation to small intestine NETs, both patients diagnosed within 1 year 
with metastatic disease (Figure 12) (Ter-Minassian et al. 2013). 





Figure 12. Survival for patients with metastatic disease according to PanNETS tumor subtype.  
Through Kaplan–Meier method, it has been verified that the median survival duration was of 5.2 years 
for the cohort overall, 7.9 years for small bowel NET, 3.9 years for PanNET, and 3.7 years for other 
NET.  Extracted from (Ter-Minassian et al. 2013). 
It is now well established that surgery is the standard recommendation for 
PanNETs treatment, since surgical resection procedure stands as the only 
potential cure.  As to metastatic approach, recent evidence reports that the 
median survival of patients that developed metastatic focus undergoing resection 
of the primary site to be 65 months versus 10 months for those without resection 
(Kelgiorgi and Dervenis 2017). Aside from this, choice of treatment is determined 
by tumor heterogenous nature and consists in a politherapeutical scheme 
involving a combination of targeted therapies, systematic chemotherapy and 
octreotide analogs (Lewis et al., 2017). 
In recent times, novel targets contributed to the discovery of new treatment 
possibilities for patients and also broadened our knowledge about the biology of 
PanNETs. The PanNETs biomarkers identification help us to predict the response 
to targeted therapy and to develop more effective targeted therapy itself, thus, 
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improves future expectations, because it brings us closer to a personalized, 
patient-tailored treatment (Kelgiorgi and Dervenis 2017).  In this way, in order to 
determine new biomarkers, increasing research with a focus on PanNETs for 
which preclinical model usage is crucial, is needed. 
5. RIP1-Tag2 as a pancreatic neuroendocrine tumor 
mouse model 
The RIP1-Tag2 is the transgenic animal model of pancreatic β-cell 
carcinogenesis, that has been used to identify several mechanisms involved with 
cancerous disease. The expression of insulin-producing islet β cells promotes 
PanNETs induction. Specifically, SV-40 large T antigen (Tag) is expressed in all 
islet cells from RIP1-Tag2 at birth under the control of the rat insulin gene 
promoter (RIP) (Figure 13). This T-antigen expression abrogates p53 and RB 
tumor suppressors in in β-cells, which elicits the sequential development of 
tumors in the islets over a period of 12–14 weeks, reaching a maximum degree 
of aggressiveness at 16 weeks of age. 
 
Figure 13. Gene construct from RIP-Tag2 animal model.  The rat insulin promoter (RIP) fusion with 
the large T antigen of simian virus 40 (SV40) promotes perturbation in the p53 and pRb pathways, 
favoring the appearance of tumors in the pancreatic islets over a period of 12-14 weeks. 
Among all islets that express T-antigen oncogene about half the 400 islets 
become hyperproliferates (Folkman et al. 1989), and, 15–20% of these 
angiogenic islets turn on into benign tumors, encapsulated lesions and invasive 




carcinomas (Lopez and Hanahan 2002). Tumor evolution occurs by stages 
(Figure 14A), in this way, hyperplastic/dysplastic islets start appearing at 3 weeks 
of age. Then, 25% of hyperplastic islets switch on angiogenic signaling between 
6 to 9 weeks (Folkman et al. 1989). The switch is determined by vascular dilation, 
microhemorrhaging, and, endothelial proliferation. At the last steps of 14-16 
weeks 2 to 10 PanNETs to each animal are found (Efrat et al. 1988). In this point, 
islet tumors in RIP1-Tag2 tumors may finally lead to liver metastasis, similar to 
what occurs in human PanNET patients. 
RIP1-Tag2 mice may develop PanNETs of different malignancy level, from 
islet tumors to invasive carcinomas. Islet tumors (IT) are tumors with well-defined 
margins, encapsulated and surrounded (Figure 14B). Malignant RIP1-Tag2 
tumors are classified according to their invasion of the adjacent tissue. Invasive 
carcinoma type 1 (IC1) shows focal regions of invasion with adjacent margins 
(Figure 14C), with tumor cells intercalated into exocrine tissue; whereas invasive 
carcinoma type 2 (IC2) presents widespread invasion with no evidence of 
margins, with extensive intercalation of tumor cells into exocrine pancreas (Figure 
15D) (Lopez and Hanahan 2002). 




Figure 14. RIP1-Tag2 tumor progression. (A) Multistage cancer progression in RIP1-Tag2 mouse 
including: normal, oncogene-expressing islets; hyperplastic islets, populated by proliferating cells; 
angiogenic islets, in which new blood vessel growth has been activated; and solid tumors, which are 
islet cell carcinomas. Modified figure from (Hanahan and Folkman, 1996). (B-D) Malignant RIP1-Tag2 
tumors classification. Hematoxylin and eosin stain of representative examples of IT (B), IC1 (C), and 
IC2 (D).  Modified figure from (Du et al. 2007). 
6. Anti-angiogenic therapies  
Tumor angiogenesis is thus defined as the process of blood vessel 
creation, penetration and growth in the tumor microenvironment. This process is 
critical to tumor growth beyond a limited size, granting oxygen, nutrients, and 
waste disposal, to thereby sustain the deregulated proliferation of tumor cells. 
Besides serving as nutrient, oxygen, and waste transport providers, vessels also 
facilitate dissemination of tumor cells to distant sites, promoting metastasis 
(Zuazo-Gaztelu and Casanovas 2018). Tumor angiogenesis is controlled by a 
balance of pro-and anti-angiogenic molecules and when the balance shifts in 
favor of angiogenesis inducers, an angiogenic switch activates the normally 
quiescent vasculature to develop new blood vessels (Hanahan and Folkman, 




1996), often concomitant with enlargement (dilation and microhemorrhaging) of 
the preexisting vasculature (Ganss et al. 2002).  
Despite the fact that PanNETs are highly heterogenous, the high 
vascularization is a characteristic common in all of these neoplasms. Thus, one 
of the approaches developed and tested for the treatment of well-differentiated 
NET tumors are anti-angiogenic strategies, in which the focus is to block some 
angiogenic factors and their receptors.  In this anti-angiogenic context, vascular 
trimming occurs, and as consequence lack of nutrients, thus, leading to tumor cell 
death. Considering the quantity of mechanisms involved in tumor angiogenesis, 
blood vessel formation may be inhibited at different levels. Nowadays, growth 
factors and tyrosine kinase (TK) receptors are the main promising targets in 
angiogenesis inhibition, and, in fact, many drugs have been developed using 
these strategies (Zuazo-Gaztelu and Casanovas 2018). 
It is important to mention that many anti-angiogenic drugs, such as 
bevacizumab and sunitinib, have been already approved by the US Food and 
Drug Administration (FDA) for the treatment of some of NET tumor types  
(Capozzi et al. 2016). Between them, sunitinib (Sutent®, Pfizer) promotes the 
inhibition of tyrosine kinase receptors involved in angiogenesis and expressed by 
endothelial and mural cells, such as VEGFR2, VEGFR3, PDGFR-α and PDGFR-
β (Mendel et al. 2003). On the other hand, this drug also inhibits a set of receptors 
involved in proliferation and cell survival expressed in tumor cells, such as c-KIT 
(stem cell factor receptor), FLT3 (Fms-like tyrosine kinase 3) and CSF-1 (type I 
receptor of colony stimulating factor) (O’Farrell et al. 2003). 
Sunitinib in RIP1-Tag2 tumors increases lifespan and delays tumor growth 
by reducing endothelial cell density and pericyte coverage of tumor vessels 
(Figure 15) (Pàez-ribes et al. 2010; Pietras and Hanahan 2005). 




Figure 15. Increased lifespan and tumor reduction in sunitinib-treated RIP1-Tag2 animals. (A) 
Kaplan-Meier survival curves in tumor-bearing RIP1-Tag2 mice treated continuously with vehicle 
control or sunitinib starting at 12 weeks. While vehicle-treated mice showed a median lifespan of 15.2 
weeks, mice receiving continuous sunitinib treatment demonstrated a survival benefit of 7 additional 
weeks. (B) Total tumor burden analysis of RIP1-Tag2 mice in 5-week treatment trials with sunitinib or 
vehicle control starting therapy at 10 weeks of age. **p < 0.01 by Mann-Whitney test. Error bars 
indicate ± SEM. Image has been adapted from (Pàez-ribes et al. 2010). 
Sunitinib’s effectivity in patients with advanced PanNETs was proved with 
a phase 3 clinical trial. As result the median progression-free survival in the 
sunitinib group increase to 11.4 months in relation to 5.5 months in the placebo 
group. In addition, enhancement in overall survival and the objective response 
rate improved 9% versus 0% in the placebo group (Figure 16)   (Raymond et al. 
2011). This data was especially important since there is a low number of effective 
treatments known for advanced PanNETs. 





Figure 16. Progression-free survival by Kaplan-Meier analysis of in sunitinib Vs. placebo in 
treated advanced PanNET patients. Among 171 (86 patients who received sunitinib and 85 patients 
who received placebo), the median progression-free survival was 11.4 months in the sunitinib group 
versus 5.5 months in the placebo group. Image has been adapted from (Raymond et al. 2011). 
6.1 Effects of anti-angiogenic therapies  
Until now, many angiogenesis inhibitors have been described, nonetheless 
only a small part of them have been approved and applied in the clinic. The critical 
point is that antiangiogenics produce a progression delay with a limited period of 
clinical benefit, rather than providing enduring efficacy in tumor shrinkage or 
dormancy (Hanahan and Bergers 2008). Specifically, the clinical benefit of 
antiangiogenic drugs remains limited due to the acquisition of tumor drug 
resistance, and progression to stages of greater malignancy. Therefore, this 
strategy need to be improved to development of enduring antiangiogenic 
therapies, and thus, guarantee patient’s long-term response (Zuazo-Gaztelu and 
Casanovas 2018). 
Some years ago, the failure of anti-angiogenic therapy in RIP1-Tag2 model 
preclinical study was described. The initial efficacy revealed an initial response 
through of vascular dropout and tumor stasis, however tumors then adapt, 
acquiring resistance and begin regrowing via a process denominated to as 
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“evasive resistance”, as demonstrated by tumor revascularization, regrowth and 
invasiveness (Casanovas et al. 2005). A time later, our group demonstrated that 
besides the phenotypic resistance to antiangiogenic therapies, an increase of the 
invasive phenotype in tumors also occurs under anti-VEGFR2 antibody (DC101) 
(Figure 17A) and angiogenic kinase inhibitor (sunitinib) (Figure 17B) treatments 
in RIP1-Tag2 tumors (Pàez-ribes et al. 2010). 
 
Figure 17. Increased invasive phenotype after anti-angiogenic therapy. Quantification of 
histological analysis of tumor invasiveness represented as the percentage of encapsulated islet 
tumors (IT), microinvasive carcinomas (IC1), and fully invasive carcinomas (IC2) for control, DC101 
(A) and sunitinib (B) treated RIP1-Tag2 mice. (A) Both anti-VEGFR2 treatments show a statistically 
significant decrease in the percentage of IT and a significant increase in IC2 tumors (∗∗p < 0.01 by 
Kruskal-Wallis test). (B) Sunitinib treatment shows statistically significant decrease in IT and increase 
IC2 tumors by Mann-Whitney test (∗p < 0.01; ∗∗p < 0.01). Error bars indicate ± SD. Image has been 
adapted from (Pàez-ribes et al. 2010). 
In order to verify other tumor malignization effects that could be identified 
after short-term treatment (2 weeks), histological analysis of lymph node (LN) was 
performed and liver metastasis after anti-angiogenic therapy. In this way, our 
group described that besides local invasion observed at acinar tissue, tumor cell 
invasion occurs into blood and lymphatic vessels, which consequently lead to an 




increase in the incidence of lymphatic and hepatic metastases (Figure 18). 
 
Figure 18. Increased incidence of lymph node and liver metastasis in DC101 treated animals. 
Histological analysis of lymph node (LN) and liver metastasis in RIP1-Tag2 animals treated with 
DC101 for 10 days starting at 10 weeks of age and then left untreated until 16 weeks of age. (A) LN 
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and Met observed by histological H&E staining of tissue sections from DC101-treated animals appear 
as enlarged hemorrhaging LNs infiltrated with tumor cells and a small tumor nodule in the liver 
parenchyma (left panels). Immunohistochemical staining for the tumor marker SV40 T antigen (brown) 
reveals the presence of tumor cells infiltrated into a LN or in the midst of the liver parenchyma (right 
panels). (B) Top: quantification of the incidence of animals with microscopic liver micrometastasis and 
macroscopic LN metastasis in the control (gray bars) and anti-VEGFR2-treated (black bars) treatment 
arms. Bottom: contingency table relating the number and percentage of animals in each 
treatment/metastasis case. Treated animals show a statistically significant increase in the incidence 
of liver micrometastasis and LN metastasis by the chi-square test (∗p < 0.05; ∗∗p < 0.01). (C) 
Quantification of the number of microscopic liver metastasis in the anti-VEGFR2 treated (black bars) 
and control (gray bars) treatment arms. Treated animals show a statistically significant increase in the 
number of liver micrometastases per animal by the Mann-Whitney test (∗p < 0.05). Error bars indicate 
± SEM. (Pàez-ribes et al. 2010). 
Knowing that there has been a demonstrated high correlation between 
tumor hypoxia, increased invasion, metastasis and poor patient outcome (Schindl 
et al., 2002; Semenza, 2002) was verified hypoxic levels in RIP1-Tag2 tumors 
treated with anti-angiogenics. As a result, the vascular trimming increased 
incidence of the hypoxic tumors in both anti-VEGFR2-treated and sunitinib-
treated animals. Thus, confirming evidences that indicates tumor cells escape 
from lack of nutrients tumor environment to better nourished locations, using 
hypoxia as a positive stimulus for invasion (Figure 19) (Pennacchietti et al. 2003). 
 
 





Figure 19. Increase of hypoxia in tumors as a consequence of anti-angiogenic treatment. 
Hypoxia in islet tumors was detected by immunofluorescence staining of pimonidazole adducts in 
sections of pancreas from control untreated animals, anti-VEGFR2 and sunitinib treatment. 
Quantitation of the incidence of hypoxic tumors was performed in long-term anti-VEGFR2-treated and 
sunitinib-treated animals and plotted as the percentage of pimonidazole-positive tumors per animal 
compared to control animals. ∗∗p < 0.01 by Mann-Whitney test. Error bars indicate ± SEM. Modified 
from (Pàez-ribes et al. 2010). 
Taken together these results elucidate a tumor adaptive effect of 
VEGF/VEGFR inhibitors. Thus, tumors respond to VEGF/VEGFR pathway 
inhibition with tumor regression or stasis and a loss of blood vessels. However, 
processes of evasive resistance to the antiangiogenic treatment are then induced 
that can enable revascularization via alternative proangiogenic signals, increased 
local invasiveness, and/or enhanced distant metastasis (Figure 20). 




Figure 20. Adaptive-evasive responses by tumors to anti-angiogenic therapies. Image from 
(Pàez-ribes et al. 2010). 
7. Previous results of the group 
7.1 Invasion cancer cell mechanism after anti-angiogenic 
treatment 
With the aim of clarifying which mechanisms are involved in invasion 
processes after anti-angiogenic therapy, the expression of some molecules that 
could act in the metastatic cascade step have been verified. 
As detailed in the introduction (section 2.1) there are many invasion models 
in cancer. Among them, the most studied is the mesenchymal invasive 
phenotype, where cells increase their ability to invade by the EMT process. 
Molecularly, mesenchymal cell invasion is characterized mainly by loss of the E-
cadherin protein, one of the main adhesion molecules and epithelial markers 
(Pàez-ribes et al. 2010). Also forming part of the adherent junctions is β-catenin, 
a protein that is generally sequestered in the cell membrane by E-cadherin, but in 




the absence of E-cadherin, β-catenin remains free in the cytoplasm and able to 
be translocated to the nucleus and activate transcription factors that will ultimately 
favor the transcription of genes involved in survival, invasion and metastasis 
(Bienz and Clevers 2000). 
Thus, E-cadherin and β-catenin expression levels were analysed after 
treatment with anti-VEGFR2 by immunofluorescence on frozen tissue (Figure 
21). Surprisingly, it was observed that both proteins increased their expression 
after the anti-angiogenic therapy agents. This fact confirmed that there was no 
expected cadherin switch, since both proteins increased their expression. 
 
Figure 21. Increase of E-cadherin and β-catenin in treated tumors. Immunofluorescence 
showing an increase of E-cadherin and β-catenin proteins in tumors treated with DC101 for 4 
weeks. The zones with the most intense marking correspond to acinar tissue, positive control of 
immunostaining. Ac = Acinar tissue; T = Tumor. Red marking: E-cadherin; green: β-catenin; blue: 
cores. Modified from Pàez-Ribes, 2010. 
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Since cell-cell junctions molecules remain intact or increase their 
expression in RIP1-Tag2 tumors after anti-angiogenic treatment, tumor invasion 
in this model does not seem to follow a classic EMT, however it seems to implicate 
mechanisms of collective tumor cell invasion. As described in detail in the first 
part of introduction (section 2.1.2), this is an alternative mechanism for tumor 
invasion in certain types of cancer, in which the cell-cell junctions are not lost. 
In addition, the increase of E-cadherin described in RIP1-Tag2 tumors 
following treatment with anti-VEGFR2 was confirmed in tumors treated with 
sunitinib. In conclusion, it appears that the inhibition of angiogenesis promotes 
the same Behaviour and molecular changes in non-hemorrhagic phenotype 
tumors, either through an inhibitor via the VEGF pathway as DC101, or through a 
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Given the crucial role of tumor cell invasion in metastatic cascade, it is key 
to establish how alterations to the tumor cell-autonomous signaling circuitry 
promote invasive behaviour. Determining how tumor cells initiate and sustain 
invasive behaviour might help improve patient diagnosis and lead to the 
development of new intervention modalities. Previous results from our group 
demonstrated a significant increase in tumor invasion as an effect of 
pharmacological inhibition of VEGF/VEGFR2 in RIP1-Tag2 mouse model. In 
addition, these results indicate that pancreatic islet tumor cells treated with anti-
angiogenic drugs invade collectively. However, collective cell invasion 
mechanisms have not yet been fully described. 
The general objective of this thesis is to characterize and validate collective 
invasion mechanisms of PanNETs tumors before and after anti-angiogenic 
pharmacological effects. 
To achieve this goal, our specific objectives are:  
1) To characterize morphologically and molecularly collective invasive 
behaviour in RIP1-Tag2 tumors and βTC4 spheroids before and after 
anti-angiogenic treatment. 
2) To select potential candidate genes involved in RIP1-Tag2 tumor cell 
collective invasion before and after anti-angiogenic therapy.  
3) To functionally validate our potential candidates in βTC4 cells and 
spheroids.  
4) To validate our potential candidates identified in RIP1-Tag2 tumors and 
βTC4 spheroids in clinical samples of neuroendocrine cancer patients. 
 
 




1. Project design  
Local invasion is a key cell-biological event in the metastatic cascade. In 
response to a changing microenvironment, cancer cells may act using two main 
strategies of invasion: single cell invasion and collective invasion. To elucidate 
which molecular mechanisms are involved in PanNETs invasion, we designed an 
experimental approach in which four steps are key to guiding this workflow (i) in 
vitro and in vivo PanNETs models identification, (ii) morphological and molecular 
PanNETs invasion characterization, (iii) selection of possible targets gene and 
(iv) target validation. Thus, in this section, I will summarize the experimental 
design applied at all stages of the project, whereas in the following sections the 
results will be described in detail (Figure 22). 
 
Figure 22. Project overview. Experimental workflow consisted in four main steps. (i)  in vitro and in 
vivo PanNETs of models determination, (ii) morphological and molecular PanNETs invasion 
characterization, (iii) selection of possible targets gene and (iv) target validation. 
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Mouse models of human cancer are an indispensable tool for studying 
tumor initiation, maintenance, progression, and response to treatment. Among 
these, previous studies demonstrated that RIP1-Tag2 mouse model is a valuable 
prototype for verifying the stepwise progression of multistage tumorigenesis 
(Hanahan, 2015). For this reason, the RIP1-Tag2 mouse proved to be the most 
accurate choice for studying invasion in PanNETs. In the same way, we will use 
the βTC4 cell line derived from RIP1-Tag2 as in vitro model. Besides 2D βTC4 
cells, other kinds of models like 2,5D and 3D models for verifying in detail the cell 
migration and invasion process will be developed. 
Due to the different types of invasion observed in cancer, in the next step 
the malignancy observed in our models from PanNETs will be characterized 
morphologically and molecularly. To this end, in vitro, in vivo and clinical samples 
will be analysed by different techniques. For example, Transwell® and 3D 
invasion assay will be used for analyzing in vitro invasion, HE staining for verifying 
invasion in vivo. To identify the molecular mechanisms involved in this process 
will apply different protein and RNA detection methodologies.  
In the screening step, the main goal will be to select genes involved with 
mechanisms of RIP1-Tag2 invasion before and after the therapy, in order to 
describe how tumor cells, initiate and sustain invasive Behaviour. For this, we will 
use GSEA analysis to compare samples from RIP1-Tag2 controls and highly 
invasive anti-angiogenic treated tumors. GSEA is a robust computational method 
that determines whether an a-priori defined set of genes shows statistically 
significant, concordant differences between both groups. GSEA analysis will 
thereby perform an association of functional profile of gene set collections pre-
established with the input gene set from samples phenotypically characterized by 
tumor malignancy increase after anti-angiogenic treatment. Through a statistical 
test, it will be possible to observe an enriched functional gene set among the input 
genes. 
In the last step, we will validate the targets relevance in the malignancy of 
PanNETs. We will perform a functional validation in in vitro and in vivo models 




through protein and RNA levels using different techniques, and in clinical samples 
by omics analysis. Different treatments we will be used to functional induction and 
inhibition of our target. Finally, invasion assays will be used to confirm a role of 











































1.    Animal procedures 
Ethics Committee approved all animal studies realized in this work for 
Animal Experimentation from the Biomedical Research Institute of Bellvitge 
(IDIBELL) and Generalitat de Catalunya. Mice were maintained in Specific 
Patogen Free conditions, in constant temperature (20-22ºC) in ventilated racks 
and manipulated in vertical laminar flow hoods in IDIBELL- Hospital Duran I 
Reynals (AAALAC accreditation number 1155). The European directives on 
ethical usage of rodents for animal research (approval DARP #4899) were met in 
all animal experiments.  
Mice were supplied of food and water ad libitum. Besides that, taking into 
consideration that β pancreatic tumor cells secrete high level of insulin was added 
sucrose to mice water to alleviate the severe hypoglycaemia that some animals 
can present. Animals were sacrificed by cervical dislocation or in case that 
physiological serum perfusion was required an overdose of the anesthetic 
Dolethal (pentobarbital sodium) was proceed. 
1.1 Animal model 
All experiments in this study were performed using RIP1-Tag2 of the 
C57Bl/6J strain. RIP1-Tag2 model have been used in several studies involving 
angiogenesis, tumoral progression and pharmacological effects. The generation 
and characterization of the transgenic RIP1-Tag2 mice (Hanahan, 1985) have 
been previously reported (detailed description in Introduction section 5). 
1.1.1 Mice genotyping 
RIP-Tag2 mice were obtained after crossing non-transgenic (wild type) 
females with RIP-Tag2 males. Weaning was performed at 3 weeks of age, in this 
moment all animals were sexed and marked for their subsequent identification. 
The remaining ear fragments were used to perform the genotyping. Pieces of the 
ear were immersed in digestion solution (50 mM Tris-HCl, pH 8; 20 mM NaCl; 1 
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mM EDTA, pH 8; 1% SDS; 2 mg/mL proteinase K (Sigma) and they were 
incubated at 65ºC during 4-12 hours. 300 μL of water were added and incubated 
at 95ºC for 10 minutes in order to inactivate proteinase K. For the PCR, in order 
to ensure optimal reaction, two pairs of oligos were used, one pair for the T 
antigen (Tag) and another pair for the endogenous control β2-globulin (Table 1).  
Sequence of the oligos: 
Table 1. Primers for RIP1-Tag2 mice genotyping and used in PCR reaction    
 
Subsequently, the loading buffer is added to the samples and run in a 2% 
agarose gel stained with SYBR Safe. To rule out contaminations possibility in our 
PCR reaction is important to include a negative control water (H2O). Finally, 
samples with 2 bands pattern will correspond to transgenic RIP1-Tag2 mice 
(RIP1-TAG2) and those showing only one band (WT) will represent wild type mice 
(Figure 23).  




Figure 23. Agarose gel for RIP1-Tag2 mice genotyping. Double band pattern relative a RIP1-Tag2 
transgenic mouse (RIP1-TAG2), a single band pattern from wild type mouse (WT) and a negative 
control of water (H2O). 
1.2 Anti-angiogenic treatments 
RIP1-Tag2 mice were treated with two different antiangiogenic drugs: 
sunitinib and DC101.  Sunitinib was provided by Pfizer and dissolved in a solution 
of carboxymethylcellulose (CMC): 0.5% CMC, 1.8% NaCl, 0.4% Tween 80 and 
0.9% benzyl alcohol (the pH was adjusted to 6). Mice were treated with 40 mg/kg 
of sunitinib daily orally for 4 weeks. DC101 is a anti-VEGFR2 blocking antibody 
that was obtained in bulk by purification from the supernatant of a hybridoma 
culture (DC101) available from American Type Culture Collection (ATCC).  
DC101 was administered at 1 mg/animal, twice a week through intraperitoneal 
injection, was performed a long (4 weeks) term treatment. 
1.2.1 DC101 production and purification 
DC101 was acquired from a cell culture of rat hybridoma seeded in 
bioreactors (CELLine CL 1000, IBS Integra Biosciences) using serum free 
medium Hybridoma-SFM (Gibco) mmented with glutamine 2 mM, 50 U/mL 
streptomicine, 1% nonessential aminoacids and 0,4% of glucose. The 
supernatant of the hybridoma, once per week, was collected and centrifuged at 
3000 rpm for 15 minutes and filtered at 0,22 μm. BCA kit (Pierce) was used for 
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the protein quantification. To determine the quality of the antibody an 
electrophoresis with a 7,5% poliacrilamide gel was performed due to the fact that 
DC101 antibody has a high molecular weight (145 kDa). To preserve the disulfide 
bonds and be able to correctly evaluate the integrity of the DC101 obtained it is 
important once the sample buffer is added to the samples not to boil them or add 
β-mercaptoethanol. Finally, in order to check the quality of DC101 obtained by us, 
a known concentration of purified antibody was loaded, as weel as, a reference 
DC101 sample (commercial DC101 supplied by ImClone) and the gel was stained 
with Comassie Brilliant Blue.  
1.2.2 Determination of the antiangiogenic effects 
To establish the potency of anti-angiogenic treatment administered, was 
performed a tumor recount in lesions which presented antiangiogenic switch. In 
this way, all those lesions are classified in relation on hemorragic aspect 
observed, being tumors are classified in hemorrhagic (red color), partial 
hemorrhagic (pink color) and non hemorrhagic (white color).   
1.3 Determination of survival time 
The RIP1-Tag2 mice of the colony were distributed randomly in the different 
treatment groups starting at 12 weeks of age. Mice were sacrificed when they 
shown severe hypothermia or hypomobility. 
1.4 Invasion determination 
Paraffin embedded samples were H&E stained and used for the invasion 
morphological determinations because only formalin fixed, and paraffin 
embedded tissues preserve their morphology and allow studding the architecture 
of the tissue. The RIP1-Tag2 tumors were classified into encapsulated tumors, 
microinvasive tumors or highly invasive tumors (Figure 24) (Lopez and Hanahan, 
2002).  
 




Figure 24. Morphology of the distinctive stages in islet carcinogenesis.  (A) Staging criteria for 
H&E-stained pancreatic sections in mouse models of islet carcinogenesis. (B) Typical examples of 
the stages evident in the pathways to islet carcinogenesis are shown for standard RIP1-Tag2 mice. 
Scale bars represent 20µm on all micrographs except the islet tumor and invasive carcinoma type 2 
in A, where the scale is 40 µm. From (Lopez and Hanahan, 2002). 
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1.5 Tumor and organ collection 
After animals sacrificed tumor and other organs were washed with sterile 
water. One part of RIP1-Tag2 tumors was fixed in formaldehyde 4% O/N to be 
included in a cassette for paraffin embedding and in sequence these were washed 
with water and dehydrated (70% ethanol, 96% ethanol, absolute ethanol and 
xylol) and submerged in liquid paraffin at 60ºC. Then, remaining tumoral tissues 
were included in OCT (Tissue-TEK® Sakura) embedding medium at 80ºC for 
further analyses of frozen tissue. Some tumors originating from different animals 
were carefully isolated from the exocrine pancreas and frozen at 80ºC in order to 
perform RNA or protein extraction. 
1.6 Histological studies 
Paraffin embedded samples were hematoxylin and eosin (H&E) stained 
and used for morphological analysis, invasion quantification and specific 
immunostaining because only formalin fixed and paraffin embedded tissues 
preserve their morphology and allow studding the architecture of the tissue. 
Paraffin sections (3-5µm) deposited into poly-L-lysine pre-treated slides 
and cut by microtome were subjected them to a deparaffinization battery (Table 
2). 
Table 2. Sequence of deparaffinization battery 
 
Then, samples were stained with H&E. Slides were submerged for 10min 
in Hematoxilyn and rinsed in tap water.  Following, they were submerged in HCL 
1% until the tissue color shifted to red and then in ammonia water solution (200ml 
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of dH2O with 1ml of ammonia 30%) until it turned back into blue. Sections were 
counterstained in eosin (2.5 g of eosin in 1L of ethanol 50%) for some seconds. 
At the end, slides were covered with coverslips and mounted using DPX 
(Merck). All tissues were visualized and photographed using the Nikon Eclipse 
80i microscope and a Nikon DS-Ri1 digital camera by NIS-Elements BR 3.2 (64-
bit) Software.  Afterwards, images were optimized and analysed with Image J 
Software. 
2. Protein analysis of tumor samples 
2.1 Immunohistochemistry 
Besides H&E stained were also performed immunohistochemistry to detect 
CDH1, CLDN4, fibronectin, cadherin-7 following the same protocol. Firstly, 
paraffin-embedded tumor samples were deparaffinised in xylene and rehydrated 
in graded alcohols (section 1.6). Subsequently antigen retrieval was performed 
with in sodium citrate solution (0.38mg/ml) pH=6 and heating for 15min. Then, 
samples were cooled down inside the citrate solution for 20-30min and washed 
with dH2O for 5min. 
The endogenous peroxidases were activity blocked with double incubation 
with 3% hydrogen peroxide for 15min.  Later samples were washed with dH2O 
for 5min and cell membranes were permeabilized with PBS 0.1% triton (PBST) 
for 5min. Afterwards, in order to reduce the unspecific unions slices were 
incubated during 1h at RT with a protein-blocking solution (normal goat serum 
diluted 1:5 in PBS) and primary antibodies (Table 3) were used for specific tissue 
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Table 3. List of antibodies used for immunohistochemistry 
 
In the next day, sections were placed at RT for 20-30min and were washed 
three times with PBS 1X for 10min. After that, samples were incubated with 
secondary antibodies anti-mouse or anti-rabbit Envision+-System-HRP (Dako) 
during 1 hour at RT.  Finally, slices were revealed with the chromogenic substrate 
DAB+ (EnVision™ Kit, Dako), from 30s to 10min, depending on the antibody and 
the samples used, until a brown precipitate appeared. The reaction was stopped 
by rinsing the slides with tap water for 10min. After, sections were counterstained 
with haematoxylin and dehydrated in graded alcohols. Then slices were mounted 
using DPX (Merck) and were covered with cover slips. The subsequent analyses 
were realized with method describe in the section 1.6.  
2.1.1 CLDN4 and CDH1 immunohistochemistry quantification 
First of all, different tumoral zones were determined in three levels, tumor 
center, invasive front and encapsulated front. Following, was determined CLDN4 
staining intensity by scoring from 0 to 2 for each tumoral zone. The values were 
plotted using tumor zone data relating with their intensities. In the second 
methodology applied, were determined the percentage of global tumor invasion 
and these levels were correlated with the CLDN4 average intensity observed in 
all tumoral zones.  
In order to determine CDH1 intensity the same method to CLDN4 
quantification was used. However, the only difference between both was that in 
CDH1 quantification were considered just periphery zones, being classified in 
invasive front and encapsulated front. The relations posteriorly applied were the 
same used in CLDN4 intensity determination. 
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2.2 Preparation of protein lysates from tumor tissues 
Tumor tissue was unfrozen on ice to prevent degradation by proteases and 
was placed in Tissue Grinder Potter-Elvehjem (TGPE) to further homogenization. 
The TGPE is graduated glass tube and a finely machined pestle, in which the 
pestle is attached to a stainless-steel shaft and homogenization occurs as the 
sample and buffer are forced through the cylindrical portion of the mortar as the 
pestle rotates downward. Thus, sample was homogenizing using TGPE with 
400µl RIPA lysis buffer (Table 4, pH 7.4) same minutes and the lysate was 
transferred into a 1.5ml Eppendorf.  It was incubated in rotation during 30-40min 
at 4ºC. At the end, sample lysate was centrifuged at 14000rpm for 15min at 4ºC 
and supernatants were stored at -20ºC.  
Table 4. RIPA lysis buffer composition 
 
2.3 Protein quantification 
Protein concentration of protein supernatants was determined using 
Pierce™ BCA Protein Assay Kit (Thermo Scientific). For acquire a stand curve 
was diluted Bovine Serum Albumin (BSA) in a set of diluted standards ranging 
from 0 to 2mg/ml and samples were diluted (1:10).  Afterwards, was prepared a 
BCA Working Reagent, it was diluited (50:1, Reagent A: B) and loaded onto a 96-
well plate. Then, of the known diluted concentrations of BSA or diluted samples 
(10µl) were loaded on plate.  It was incubated at 37ºC for 20-30mins and then 
Materials and Methods  ____________________________________________________  
 
82 
absorbance was measured at 560nm by spectrophotometry (Power Wave XS, 
BIO-TEK) using the KCJr Win Software.In this way, protein concentration was 
calculated by extrapolation in the BSA standard curve. 
Finally, lysates were mixt with loading buffer (Table 5) at a final 
concentration of 1:4 and were incubated 5min at 95°C to contribute with 
denaturalisation already started for the presence of SDS and β-Mercaptoethanol. 
The final blend was stored at -20ºC. 
Table 5. Loading buffer elements   
 
2.4 Western blotting 
In order to separate proteins by size was applied Sodium dodecyl sulphate 
polyacrylamide gels (SDS-PAGE) technique. To meet its goal SDS-PAGE 
technique has two-phase gels: the stacking and the resolving gel (Table 6). The 
stacking gel is responsible to stacks the proteins to enter into the resolving gel. 
On the other hand, the resolving gel is responsible for separating proteins by their 
molecular weight. Thus, depending on the molecular weight of the protein of 
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Table 6. Western blotting gels composition  
 
The wells of SDS-PAGE were carefully loaded with 30µg of protein into gel 
along with a molecular weight marker (Page RulerTM prestained, Thermo 
Scientific) into running buffer 1X (Table 7). After that, protein samples were 
submitted to electrophoresis at 100V for 60min to 120min.  Then, the acrylamide 
gels were transferred to a nitrocellulose membrane (Immobilon-P, Merck 
Millipore) at 100V for 120min that was previously activated with methanol. 
Table 7. Running buffer compounds 
 
The membrane was blocked with 5% skimmed milk in TBS (Tris 50mM, 
NaCl 150mM) for avoiding unspecific bindings. Then, membrane was incubated 
with primary antibodies in TBST 1% skimmed milk in appropriate dilutions (Table 
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Table 8. List of primary antibodies used for western blotting 
 
The following day, membranes were washed three times, 10 min each, 
shacking with TBS- 0.1% Tween 20 (TTBS) and then, blots were incubated with 
secondary antibodies (Table 9) in 1% skimmed milk in TBS for 1 hour at RT and 
more one-time blots was washed thrice with TBST. 
Table 9. List of secondary antibodies used for western blotting 
 
In order to verify if the antibody was hybridized to the protein of study, the 
membrane was incubated with an Amersham ECL Select™ Western blotting 
detection reagent (GE Healthcare Life Sciences) according to manufacturer’s 
instructions and exposed ChemiDoc System (Bio-Rad). Finally, protein 
quantification was performed through densitometry analysis of bands intensity 
was performed using Image Lab software (Bio-Rad). 
3. Molecular analysis of tumor samples 
3.1 RNA extraction 
Once mice sacrificed the tumors were collected and the surrounding acinar 
tissue was carefully removed. Afterwards, tumors were placed in Eppendorfs, 
homogenized manually and RNA was extracted with RNeasy Plus kit (Qiagen) 
following the manufacturer’s instructions. Obtained RNA was quantified in the 
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spectrophotometer NanoDrop TM1000 (Thermo Scientific). To validate the RNA 
obtained was loaded a 500ng of RNA in a 1% agarose gel using a 1Kb Plus DNA 
ladder (Invitrogen). Contaminated with samples gDNA were treated with DNA-
freeTM DNA removal kit (ThermoFisher Scientific), following manufacturer’s 
instructions. Finally, the RNA obtained was quantified in the espectophotometer 
NanoDrop TM 1000 (Thermo Scientific). 
3.2 Obtention of cDNA from mRNA 
The mRNA samples with 20μl mix composed of 2μg of RNA together with 
Mix RT-PCR were converted into cDNA using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems).  For this, 10µl of this Mix RT-PCR was 
added to each cDNA sample and the reverse transcription reaction was 
performed with the following conditions (Table 10) 
Table 10. Mix RT-PCR components and PCR conditions for convert cDNA in mRNA 
 
Obtained cDNA was stored at -20ºC until use. 
3.3 Real-Time Quantitative PCR (RT-qPCR) 
In order to determine an expression level of our interest genes we 
performed a Real-Time PCR technique. RT-qPCR is a PCR in which amplification 
products number are known. First of all, plate was loaded with 5µl of TaqMan® 
Universal PCR Master Mix (Applied Biosystems), 25ng cDNA obtained from 
different tumor tissues, 0.5µl of the Taqman® Probe of interest (table W) and 
ddH20 to a final volume of 10µl. The plate was read on a HT7900 Real-Time PCR 
System (Applied Biosystems) following the program (Table 11): 
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Table 11. Real-Time PCR conditions 
 
Obtained results were visualized analysed by RQ Manager and SDS 2.4 
softwares (Applied Biosystems).   
Results from amplification curves are calculate by the Ct (threshold cycle). 
Ct is the cycle in which the fluorescence over the background is significant, being 
inversely proportional to the copy number. In this way, the final number of cycles 
detected for fluorescent signal for each gene was normalized against the same 
value of the housekeeping gene, being in this thesis the ACTB gene. To calculate 
a final value of RNA expression was applied the following formula: 
2−∆𝐶𝑡 =   2−(𝐶𝑡𝑔𝑒𝑛𝑒 𝐴−𝐶𝑡 ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒) 
4. Cell culture techniques 
In this work, βeta Tumor Cell 4 (βTC4) cell line was used in all in vitro 
experiments. βTC4 cell line was isolated from RIP1-Tag2 tumors in Hanahan 
laboratory and maintained in DMEM (Lonza), 15% FBS supplemented with 1% 
nonessential aminoacids, 1% piruvate and 100 μg/mL penicillin-streptomycin (all 
from Life Technologies). SN12C and Ren13 cell lines were also used as protein 
positive controls markers when it is needed (Table 12).  
Table 12. List of cell lines used in this thesis 
 
SN12C and Ren13 cell lines have human kidney tissue origin. SN12C was 
provided F. Setién and Manel Esteller from the cell culture facility of the Cancer 
Epigenetics and Biology Program (PEBC) and was cultivated in DMEM (Lonza), 
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10% FBS with 50U/ml of penicillin, 50µg/ml of streptomycin sulfate, 2mM of L-
glutamine, 10mM of HEPES, 1% pyruvate and 1% of non-essential aminoacids 
(Table 13) (all from Gibco, Life technologies). Ren13 renal cell carcinoma is a 
primary cell line previously established in our group maintened in RPMI 1640 
(Gibco), 10% FBS, 10ng/ml EGF (Bionova), 0,72 ug/ml insulin (Lilly) and 
supplemented as SN12C.  
Table 13. Media used for cell culture 
 
4.1 Mycoplasma test 
In order to check mycoplasma contamination was performed routinely PCR 
in all cell lines using the oligonucleotides (Table 14). As a template for the PCR, 
media from cells, which had been in overconfluence and absence of antibiotics 
for, at least 5 days were used. If the result was positive, cells were treated with 
PlasmocinTM at 25µg/ml for 2 weeks, and then cells were tested again for 
contamination. 
Table 14. Primers for the detection of mycoplama 
 
4.2 Cell freezing and cryopreservation 
βTC4 cells were washed with PBS, resuspended in culture medium and 
transfer into a 50 mL falcon tube, in other cell lines we performed the trypsinization 
in this moment. After, cells were centrifuged for 5 min at 1,250 rpm at room 
temperature and was removed the supernatant and loosed the pellet gently. Cells 
of a p100 plate were resuspended in cold freezing medium (90% FBS plus 10% 
DMSO (Sigma) without dilution, already renal cells were diluted in ½ or ⅓, 
depending on the cell line. 
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Cell suspension was transferred in cryovials at 1ml/tube and put into a -
80°C freezer. In this process, we used a container that will ensure that the 
temperature decreases steadily by 1°C/minute. After 24h, we transferred the 
cryovial into liquid nitrogen for long-term storage. 
To cell thawing, the cryovial containing the frozen cells was removed from 
liquid nitrogen and quickly place it into 37°C water bath (< 1 minute). After, cells 
were diluted in prewarmed medium, trespassed to a 15ml falcon tube and cells 
were centrifuged for 5 min at 1,250 rpm at room temperature. Finally, cells were 
gently resuspended in complete fresh medium and transferred them into the p100 
plate with recommended culture environment. 
4.3 βTC4 spheroids 
Cellular aggregates from βTC4 spheroids were spontaneously generated 
during the 2D in vitro culture of βTC4 cells, these aggregates were denominated 
βTC4 spheroids. βTC4 spheroids were cultivated in the same conditions that 
βTC4 cells with DMEM (Lonza), 15% FBS supplemented with 1% nonessential 
aminoacids, 1% piruvate and 100 μg/mL penicillin-streptomycin (all from Life 
Technologies) onto a p100 plate. To select spheroids by size, spheroids plates 
were washed with PBS and after spheroids were resuspended in culture medium 
and filtered with cell strainer (Corning) of 40um and 70um depending on the goal 
of the assay. 
4.3.1 2,5D in vitro model 
In order to obtain 2,5D in vitro model, plate of 24 wells were coated with 
Collagen I (Corning), Gelatin (Life Technologies), Laminin (Corning), Collagen IV 
(Corning) and Matrigel® (Corning) and the plate was incubated at 37ºC for 1 hour. 
After, wells were washed with PBS, then βTC4 spheroids suspension was seeded 
into plate and βTC4 spheroids seeded were covered with 1ml of culture medium.  
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4.3.2 3D in vitro model 
A 3D model of βTC4 spheroids was established by using Matrigel® matrix 
Growth Factor Reduced (Matrigel® GFR, Corning) so as to better mimic the in 
vivo conditions in RIP1-Tag2 tumors. Matrigel® GFR is primarily composed by 
laminin, followed by collagen IV and heparan sulfate proteoglycans. Thus, it 
effectively mimics the extracellular matrix of most tumors. Regarding 3D model 
generation, a βTC4 overconfluent p100 plate is equally handled, using a 70 µm 
nylon cell strainer (Falcon Corning) to exclude smaller spheroids. Retained 
spheroids are collected in a 15 ml Falcon tube and allowed for physical 
decantation for 2-4 minutes. Spheroids at the bottom are placed in an Eppendorf, 
diluted 1:10 in fresh βTC4 media, and they are ready to use. 
When growing the isolated spheroids within a 3D matrix, 30 μl of cool liquid 
Matrigel®® were placed in each well of a 24 well plate. Importantly, at this time 
heat a little bit under the plate, to prevent the spheroids falling to the bottom of 
the drop. Then, 5 μl of previously filtered spheroids were added to the gel in a 
drop and were gently mixed, avoiding bubble formation. We repeated this process 
once more and when we got a correct confluence the plate was incubated at 37°C 
during 30min. Finally, was added 1ml of medium cell culture in each well and 
renewed every 3-4 days. Finally using an inverted microscope (Leica DMi1), was 
verified a correct spheroids confluence and position into Matrigel®.  
4.3.3 Spheroid harvesting procedure 
In 3D model, in order to allow for harvesting of intact spheroids for protein 
analyses was applied Trevigen’s Cultrex® Organoid Harvesting Solution. This 
solution provides a non-enzymatic method for depolymerizing extracellular matrix 
proteins.  
Thus, on ice were aspirated the cell culture media and spheroids plates 
were washed with cold PBS (4ºC) carefully for not to disrupt basement membrane 
matrix containing organoids. After, 100μl for each 10ul of Matrigel® of Organoid 
Harvesting Solution were added in the plate. Subsequently, the plate was 
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incubated at 4 °C for 30 – 90 minutes with moderate shaking. This incubation was 
complete when the basement membrane matrix dome was no longer visible at 
the bottom of the well and the organoids may be seen floating at the bottom of 
the well.  
Once the gel depolymerizes, contents were transferred to 15 ml or 50 ml 
conical tube and spheroids were centrifuged 600RPM for 15 minutes at 4 °C.  
After centrifugation, was aspirated the supernatant and was reserved the pellet 
contained isolated organoids. Using this pellet from in vitro 3D model of βTC4 
spheroids is possible to cryopreserve spheroids, as well as, develop processes 
for biochemical analysis (such as RT-PCR, MS-PCR, sequencing, Western Blot, 
ELISA, or IHC). 
4.4 Cell treatments 
4.4.1 Hypoxia and nutrient deprivation 
βTC4 cells and spheroids were routinely maintained in normoxia at 21% 
O2, 5% CO2, 37°C a full medium (100% nutrients). Furthermore, in order to mimic 
in vitro the anti-angiogenic treatment, cells and spheroids were cultured under the 
following conditions: hypoxia at 3% or 10% O2, 5% CO2, 37°C, different levels of 
dilution media in PBS1X or variable percentage of FBS (Table 15) all for 24 hours.  
Table 15. βTC4 cell treatment 
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4.4.2 Y201636 treatment 
βTC4 cells and spheroid were treated with YM201636 inhibitor in order to 
block CLDN1 functionally. YM201636 inhibit constant recycling of claudin-1, that 
as a consequence it to accumulate intracellularly. YM201636 is a potent inhibitor 
of mammalian phosphatidylinositol phosphate kinase PIP5KIII (PIKfyve). PIKfyve 
is the sole enzyme for PtdIns(3,5)P2 biosynthesis that regulates a number of 
intracellular membrane trafficking pathways. 
This drug has been demonstrated effectively to block CLDN1 in vitro at 
400nM, in both 2D and 3D model the concentration of Y201636 was of 400nM 
(one dosis). To verify cell morphology and viability, cells were treated and 
analised 24 hours after, respectively, by photos taken using an inverted 
microscope (Leica DMi1) and trypan blue assay. 
4.5 Migration assay in 2,5D model 
βTC4 spheroids were seeded in the coatings using the protocol described 
above (section 4.3). Then, for the spheroid adhesion to the coating, plate was 
placed was at 37°C for 3h. After these hours, using a microscope, spheroids to 
be studied were manually marked and photos were taken using an inverted 
microscope (Leica DMi1), spheroids were manually counted. In order to observe 
cell migration movement, photos of marked spheroids were also taken at 24h and 
48h. 
In the time-lapse experiment using a 2,5D model, the spheroids were 
seeded in 24 wells plate previously coated with Matrigel®, laminin. After two 
hours, the plate was positioned to take photos each 20 minutes during eight hours 
of spheroids selected. All time-lapse assay was using the objective 10X and Zeiss 
Apotome microscope. 
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4.6 Invasion assays 
4.6.1 Transwell® invasion assay  
To compare an invasion capacity of βTC4 cells we performed a Transwell® 
assay βTC4 cells (5.0 x 105 cells/mL) in 250ul of βTC4 DMEM medium were 
placed in in the 6.5 mm inserts of the Transwell®® Permeable Supports (Corning) 
containing a 8 μm polycarbonate membrane. At the bottom of the well, also 750 
µl of pre-warmed βTC4 DMEM medium.  Cells were maintained in normoxia at 
21% O2, 5% CO2, 37°C.  
βTC4 cells were treated according the objective in detail described in 
Results section. However, the last part is the same in all assays. Thus, after 
Transwell® chamber be incubated for 24h/48h, for the purpose of analysis 
remove non-invading cells the inserts were removed, wiped with a cotton swab 
on the lower part of the chamber. The membrane was fixed with methanol, 
washed with PBS 1X and stained with hematoxylin (0.1% Hematoxylin, Merck 
Millipore, in ethanol 96%) all steps for 2 minutes. 
 At the end, the membrane from inserts was removed and mounted with 
water on a slide. Using a Nikon 80i microscope and Nikon DS-Ri1 digital camera 
were taken some 20-25 representative fields at 20x magnification. Photos were 
processed and analysed with NIS-Elements BR 3.2 (64-bit) Software and Image 
J Software. All control and experimental groups performed in parallel and in 
duplicates or triplicates 
4.6.2 3D spheroid invasion assay 
A major advantage of 3D spheroid invasion assay is that we can verify the 
collective invasion capacity of a deeply manner contemplating all its aspects. For 
this, first of all was necessary to establish an in vitro 3D model as described above 
(section 4.3.2). After 24h of the spheroids already in Matrigel® manually using the 
microscope an inverted microscope (Leica DMi1), spheroids were manually 
counted and marked. In this moment, the protrusions resulting from the collective 
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invasion were quantified by each spheroid under analysis, was made a mean 
among all spheroids analysed by condition.  
The analysed spheroids have a n of 25-90 spheroids per condition. This 
quantification process was repeated every day of the assay. In the last day of the 
experiment, (day 7) spheroids already have an extreme invasion increasing the 
risk of the incorrect quantification of the protrusions. Thus, the quantifications 
analysed were until the three or sixth day of experiment. 
 YM201636 treatment in 3D model  
To verify CLDN1 block effect in 3D model, we performed a 3D model 
methodology described in the section 4.3.2. Then, in the day 0, βTC4 spheroids 
were treated with YM201636 at 400nM. The strand per spheroid quantification 
was performed at day 0, 1 and 3.  
5. In vitro protein detection 
5.1 Immunocytofluorescence 
5.1.1  2D model 
The first step realized was to treat coverslips with ultraviolet radiation during 
1-2 hours to sterilization and after placing it in a 24 well plate. βTC4 cells were 
resuspended in 5ml of full medium and 150ul of this suspension was seeded on 
a plate. The plate was maintained in normoxia at 21% O2, 5% CO2, 37°C a full 
DMEM medium (15% of FBS) during 24-72h until reached a correct confluence 
(80%). 
 Then, wells were washed with PBS and fixed for 8min with 4% 
Paraformaldehyide (PFA). Subsequently, cells were washed three times with PBS 
and permeabilized during 15min with PBS-0.1% Triton (TPBS). In order to prevent 
unspecific binding of primary antibody, cells were blocked with 20% serum of the 
species of secondary antibody (normally goat serum) in PBS for 30min at RT.  
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Afterwards, cells were incubated with primary antibodies at the 
corresponding dilution (Table 16) in blocking solution for 1h at RT and were 
washed twice with PBS. Then, secondary antibodies diluted 1/200 also with 
blocking solution for 1h at RT was applied. Furthermore, all incubations were 
performed in a humidity chamber and was used parafilm for tighten the coverslips 
over the drops.  
Finally, cells were washed with PBS thrice more and incubated for 10min 
in RT with DAPI to perform nuclear staining. Slides were mounted using 
FluoromountTM Aqueous Mounting Medium (Sigma)and Cells were observed 
using Nikon Eclipse 80i microscope, images were taken by Nikon DS-Ri1 digital 
camera using NIS-Elements BR 3.2 (64-bit) Software and were analysed using 
Image J Software. 
Table 16. List of primary antibodies used for immunocytofluorescence 
 
5.1.2 3D model 
This method is particularly useful in verifying protein expression in 3D 
spheroid invasion assay in different zones of spheroids as the necrotic center, the 
peripheral zone and protrusions from invasion. After the established 3D spheroid 
invasion assay, were waited approximately three days for the spheroids invasion 
into Matrigel®. At this moment, when the spheroids had significant levels of 
invasion the immunofluorescence technique was applied. Due to the presence of 
the extracellular matrix where the spheroids were submerged, a few steps were 
performed to facilitate penetration of the antibodies into the Matrigel®. 
Thus, the spheroids in Matrigel® were washed with PBS carefully and were 
fixated using PFA 4%. After spheroids has been washed thrice with PBS, were 
permeabilized for 30min with PBS-0.4% Triton and washed one more time. Then, 
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the spheroids were blocked with 4% of serum of the species of the secondary 
antibody (normally goat serum) in PBS-0.2% Triton for 45min at RT. 
Following a blocking step, spheroids were incubated with primary 
antibodies at the corresponding dilution (Table 16) in 1% serum in PBS-0.075% 
Triton for over weekend (72h) at 4°C covered for aluminium foil. Afterwards, wells 
were washed thrice with PBS and were applied secondary antibodies diluted 
1/200 in 2% of serum in PBS together with DAPI during 2h at RT. Additionally, all 
incubations during thi protocol were performed in shaker. 
Lastly, wells were washed thrice more and slides were gently mounted 
using a Mowiol® (Sigma-Aldrich) mounting media, after 12 hours drying the 
spheroids were already ready for analysis. To obtain a high 3D resolution of 
spheroid staining, images were taken by Leica TCS SP5 of confocal microscopy 
using the Leica LAS AF software and images were analysed by Image J Software. 
5.2 Western blotting 
To verify protein levels in in vitro samples western blotting technique was 
performed. Almost all steps during the western blot procedure from in vitro 
samples share the same in vivo tissue protocol that was previously described in 
the section  2.2, 2.3, 2.4. However, only the step of protein extraction differs from 
the protocol previously described and so will be detailed below. Protein lysates 
from 2D and 3D model was performed respectively from p100 plates of βTC4 cells 
with 90-100% of confluency and pellets from spheroids βTC4 obtained though 
spheroid harvesting procedure described in section 4.3.3.   
In 2D model, the cells were washed twice with PBS and 300μl-500μl of 
RIPA lysis buffer were added into the plate. After 5min in ice, cells were scraped 
using a cell scraper (Sarstedt) and place to an Eppendorf. In the other hand, in 
3D model a pellet from βTC4 spheroid was mixed with 200μl of RIPA and 
incubated during 5min in ice.  Finally, both kind of samples were incubated in 
rotation during 30-40min at 4ºC. At the end, samples lysates were centrifuged at 
14000rpm for 15min at 4ºC and supernatants were stored at -20ºC. 
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6. In vitro molecular analysis 
βTC4 cells and pellets from spheroids βTC4 (section 4.3.3) obtained 
through spheroid harvesting procedure were homogenized manually and RNA 
was extracted with RNeasy Plus kit (Qiagen) following the manufacturer’s 
instructions. RNA extraction, quantification, cDNA obtention and RT-qPCR were 
performed using the same procedure detailed for tissues (section 3.1, 3.2, 3.3).  
7. In silico clinical samples analysis  
Clinical data from PanNETs was obtained from independent gene 
expression study of a set of mRNA transcriptomes of PNET patients from the 
public database Gene Expression Omnibus (GEO) in which the Genome of 
reference is GSE73338 (Missiaglia et al., 2009; Sadanandam et al., 2015). 
Dataset analysed comprised 90 samples of a PNET study containing normal 
pancreas, normal pancreas islets, primary non-functional tumors, primary 
functional tumors (insulinomas), and metastases from non-functional primary 
tumors.  
In order to compare our candidate genes in three tumoral progression 
stages, we grouped clinical data from PanNETs in: primary non-malignant tumors, 
primary malignant tumors and metastasis. Thus, our analysis was performed 
using 63 non-functional primary tumors, in which 31 had synchronic metastasis 
and were determined as malignant primary tumors. In this group of 31 patients, 7 
samples were from liver or lymph node metastases. Finally, the 26 non-functional 
primary tumor patients did not have metastasis were classified as non-malignant 
primary tumors (Missiaglia et al., 2009; Sadanandam et al., 2015). 
8. Statistical analysis  
In order to compare small samples size that in fact not were normally 
distributed, a non-parametric suitable test for each case was used (Mann-
Whitney).Two-sided and unpaired tests were used for data analysis. Differences 
were considered statistically significant at p<0.05. Statistic coding: *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. GraphPad Prism v6 software 
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1.    Invasion morphological delineation  
To characterize the phenotype of cancer cell invasion on PanNETs before 
and after the therapy, first of all, we needed to determine which types of invasion 
morphologies are found in our in vivo, in vitro models. 
1.1 RIP1-Tag2 mouse model 
RIP1-Tag2 is a transgenic animal model of PanNETs that at tenth weeks of 
its life begin to present solid tumors, in which after 12-13 weeks of age progress 
to larger adenomas or invasive carcinomas. In addition, as described in 
Introduction section 6.1 (Figure 18), results from our group demonstrated an 
irreversible increase in the incidence of invasive tumors during anti-angiogenic 
treatment in the RIP1-Tag2 mouse model. For this, to describe the invasive 
morphology from RIP1-Tag2 we chose controls and anti-angiogenic treated 
tumors at 16 weeks.  
First, in relation to treatment applied, sunitinib-treated tumors showed a 
higher invasive capacity. However, this invasion increasing does not change the 
invasion morphology observed. Thus, control and sunitinib-treated tumors, in 
terms of morphology, share the same type of invasion as can be seen in Figure 4. 
The histo-morphological characteristics of invasion in these tumors 
revealed a very distinct invasion pattern, not resembling single cell invasion 
(ameboid or mesenchymal) but rather a collective type of invasiveness, in which 
overall features from individual invasion are lost. Tumor cell movement from 
pancreatic islet seems to be organized, which allows invasive cells to maintain 
high levels of cell-cell junctions molecules and communication between cells 
during the invasion process. 
 
 




To determine the cancer cell collective invasion in RIP1-Tag2 control and 
treated tumors, the three hallmarks that characterize collective movement were 
confirmed: (i) the cells remained physically and functionally connected during the 
movement, (ii) the force for migration was maintained by supracellular 
organization and, (iii) moving cell groups modified the tissue along the migration 
path (Figure 25).  As for morphology, we classified the invasion in RIP1-Tag2 as 
a coordinated collective invasion, when more than 10 cells invade connect across 
a tissue surface and remaining attached to a large tumor mass. 
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Figure 25. Morphologically RIP1-Tag2 tumors presented coordinated collective invasion before 
and after anti-angiogenic treatment. Hematoxylin and eosin staining was performed on tumor tissue 
(paraffin embedded samples) before and after sunitinib treatment (4 weeks). Front tumor invasion was 
highlighted with a white dotted line (T = Tumor; Ac = Acinar Tissue; IF = Invasive Front). Images at 4X, 
20X and 40X. 




1.2 βTC4 in vitro 2D, 2,5D and 3D model 
The βTC4 cancer cell line was derived from PanNETs tumors from RIP1-
TAG2 mouse. Interestingly, during βTC4 cells in vitro culture maintenance, we 
verified specific adhesion characteristics in these cells. For example, as previously 
described by Hanahan (Efrat et al. 1988), βTC4 cells must be cultured at high 
confluency, being essential a cell-cell contact for the maintenance and growth of 
these cells. In addition, we observed the spontaneous appearance of cellular 
aggregates during βTC4 cells maintenance that can be defined as βTC4 spheroids 
(Figure 26A). 
βTC4 spheroids are formed by a necrotic core with an intermediate layer of 
quiescent cells and another outer layer of proliferating cells, thus, simulating an in 
vivo tumor structure (Figure 26B). In this context, we hypothesized that inserting 
the spheroids into structures that favor invasion and migration steps should be a 
useful method to verify the morphology of βTC4 cells in these processes. To be 
able to confirm this hypothesis, we set up an in vitro two- and three-dimensions 
assay using βTC4 spheroids. To determine which extracellular matrix was able to 
maintain the βTC4 cellular adhesions morphology, the βTC4 spheroids Behaviour 
was verified in the following coatings: Matrigel®, Collagen I, Gelatin, Laminin and 
Collagen IV (Figure 26C). 
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Figure 26. βTC4 spheroid characterization. (A) Spheroids spontaneously generated during βTC4 
cell culture. βTC4 cell and spheroids cultured in DMEM 15%FBS medium, images at 4X, 10X, 20X, 
40X. (B) βTC4 spheroid structure. (C) βTC4 cells during 24 hours on different coatings, Matrigel®, 
collagen I, gelatin, laminin and collagen IV, images at 10X. 




As shown in Figure 26C, the spheroid structure network was only 
maintained in Matrigel® and laminin coating. In compositional aspects, besides 
laminin, the Matrigel® is composed of collagen IV, heparin sulfate proteoglycans, 
entactin/nidogen, and several growth factors. Matrigel® is a complex natural cell 
matrix derived from mouse sarcoma basement membrane and the more complete 
scaffold to mimic in vivo environments for 2,5D and 3D βTC4 spheroids 
applications. 
As mentioned before, during this thesis were used in vitro 2D, 2,5D and 3D 
models (Figure 27). The terms ‘2D model’ and ‘2,5 model’ are used here 
unchangeably to mean: Matrigel® coating presence or absence, and single cells 
and spheroids selection or not. In 2D model cells are placed in a no coating plate 
and may contain spheroids in its composition or not (Figure 27A-D). Both models, 
2,5D and 3D, were designed only with βTC4 spheroids. In the 3D invasion assay, 
βTC4 spheroids were embedded in Matrigel® and βTC4 cells invade the 
surrounding 3D extracellular matrix generating strands (Figure 27I-J). On the 
other hand, 2,5D migration assay was thought to verify migration process in the 
absence of the physical constraints imposed by the extracellular matrix, for this, 
only βTC4 spheroids were seeded on a Matrigel® coating and were observed 
during 24h-36h (Figure 27E-H). Then, through in vitro βTC4 spheroid models that 
mimic a tumor micro-region from RIP1-Tag2, it was possible to study both the 
invasion and migration patterns by 2,5D and 3D assays set-up in this project. 
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Figure 27. βTC4 in vitro 2D, 2,5D and 3D models. (A) Illustration of the 2D model. (B-D) 2D model 
from βTC4 cells/spheroids in plate. Images at 4X, 10X, 20X. (E) Illustration of the 2,5D migration assay. 
(F-H) 2,5D model containing βTC4 spheroids in Matrigel® coating for 24 hours. Images at 4X, 10X, 
20X. (I) Illustration of the 3D invasion assay.   (J-L) 3D invasion model formed by βTC4 spheroids 
embedded in Matrigel® after 48 hours of invasion. Images at images at 4X, 10X, 20X. 
Next, we focused our attention on the in vitro models in detail and their 
invasion/migration behaviour. On the first day, spheroids from 2,5D assay 
presented migrating cells (Figure 28B), revealing differences in comparison to 2D 
model, where spheroids directly planted on the plate did not initiate the cellular 




migration (Figure 28A). As we can see in Figure 28B, migrating cells from 
spheroids appear to move in concert, without completely disrupting their cell-cell 
contacts and without dispersing by the Matrigel®. 
 
Figure 28. βTC4 migrating cells in 2D and 2,5D model. (A) βTC4 spheroids without coating placed 
directly on plate after 3, 24 and 48 hours. (B) βTC4 spheroids in Matrigel® coating after 3, 24 and 48 
hours of migration. Images at 20X.  
We also noticed that βTC4 spheroids were highly invasive in the 3D assay. 
Spheroids started to present invasive properties on day one into Matrigel® (Figure 
29B). Although, only three days after it was possible to verify a high differential 
between invasive or non-invasive spheroids. An invasion peak was verified at day 
six, when 95% of all spheroids invaded on extracellular matrix (Figure 29A). As it 
is shown in Figure 29C, spheroid invasive fronts keep multicellular structures such 
as, strands, protrusions or clusters remaining from a cohesive movement, 
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Figure 29. βTC4 invading spheroids in 3D model. βTC4 spheroids embedded in Matrigel® cultured 
in βTC4 cells normal conditions (DMEM 15% FBS).  (A) Invasive βTC4 spheroids percentage in 
relation to the total spheroids (n=2).  (B) Collective invasion morphology at day 1, day 4 and day 6. 
Images at 10x. Zoom from 10X images. (C) DAPI staining of invasive βTC4 spheroids submerged in 
Matrigel®.  
In addition, to further characterize βTC4 spheroids as to collective invasion, 
proliferation and cytoskeletal structure, we performed an immunocytofluorescence 
using 3D model.  In this way, we chose CDH1 and CTNNB1 proteins as epithelial 
markers, Ki67 to verify proliferation, and F-actin as cytoskeleton marker (Figure 
30). In addition, to further characterize βTC4 spheroids as to collective invasion, 
proliferation and cytoskeletal structure, we performed an immunocytofluorescence 




using 3D model.  In this way, we chose CDH1 and CTNNB1 proteins as epithelial 
markers, Ki67 to verify proliferation, and F-actin as cytoskeleton marker.  
 
Figure 30. βTC4 spheroids besides proliferative, showed epithelial markers in their invasive 
fronts and cytoskeleton markers throughout its structure. βTC4 spheroids after four days of 
invasion in Matrigel® cultured in normal conditions (DMEM 15% FBS). Immunocytofluorescence of (A) 
CDH1, (B) CTNNB1, (C) F-actin, and (D) Ki67 and F-actin were performed. DAPI was used to perform 
nuclear staining. Images at 20X. 
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As expected due the collective invasion morphology determined previously, 
group of cells from invasive strands express epithelial markers as CDH1 and 
CTNNB1 (Figure 30A-B). On the other hand, F-actin protein was verified mostly 
localized in the center of the spheroid (Figure 30C), probably maintaining the 
cytoskeletal structure and generating traction/protrusion force to migration. Finally, 
we confirmed that, all spheroid zones are proliferative, given that cells marked by 
Ki67 was found in all spheroid zones, demonstrating that our 3D model maintains 
cell viability and proliferation (Figure 30D). 
Together, these in vitro data suggest that βTC4 spheroids invasion and 
migration process does not follow the traditional mesenquimal invasion concept, 
when cells invade the peritumoral stroma by single cells invasion mechanism, but 
it rather involves cell groups whose collective behaviour defines malignant 
function. 
Moreover, in vitro culture, we notice two subpopulations of βTC4 spheroids 
with different tumor malignancy capacity. That is, we detected in βTC4 spheroids 
the same characteristic that occurs in many tumors in vivo, the intra-tumor 
heterogeneity. In this context, cancer cells can exhibit distinct morphological and 
phenotypic profiles within the same tumor as a consequence of genetic change, 
environmental differences, and reversible changes in cellular properties  
(Meacham and Morrison 2013).  Specifically, in βTC4 spheroids, different 
passages of spheroids were cultured in small plates long-term, due to the features 
variability observed in this technique, we checked different parameters of spheroid 
culture before the experimental procedure. During this step, was noted that two 
populations of βTC4 spheroids with a very high differential as for invasion capacity, 
then, we used the term “high” to more invasive spheroids and “low" to spheroids 
with less invasion level. 
To confirm these Behaviour differences, we started analyzing migration 
capacity between high and low βTC4 subpopulations using 2,5D model migration 
assay in different coatings. The first conclusion was that the high and low 




spheroids in plate, laminin, and gelatin did not show relevant comportment 
alterations (Figure 31A-B).  
Given the relevant characteristics observed in 2,5 migration assays, we 
refine this analysis through a time-lapse in vivo assay. In this experiment, we might 
follow the sequential migration movement. Thus, we did not observed differences 
in plate and laminin conditions by time-lapse continues analysis (Plate videos: 
1.a (high), 1.b (low), Laminin videos: 2.a (high), 2.b (low); supplemental 
material). 
As seen previously, when Matrigel® coating was used, βTC4 cell from 
spheroids showed migration in both high and low subpopulations. In more depth, 
high cells exhibited a migration in which the cell-cell junctions are not lost, as 
originally βTC4 cells act. On the other hand, low cells migrating independently of 
one another and, thus, they appeared not to maintain cell-cell junctions unlike high 
cells (Figure 31C).  
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Figure 31. High cells migrated on the Matrigel® without lost the cell-cell contacts. (A-B) High 
and low spheroids were placed into plates or different coatings: gelatin, laminin and Matrigel® (C) High 
and low βTC4 cells at 48hs of migration in Matrigel® coating. Images at 20X. 
In time-lapse analysis, high subclone movement always are maintained a 
connection point between the cells, confirming their cluster migration capacity. 
However, low cells do not function within this mechanism. In this case, a 
disconnection, in which leader cells started to advance by single cell migration 
process was observed, but, as these cells were not connected they retreated their 
way in search of other cells, not allowing an efficient migration (Matrigel videos: 
3a (high); 3b (low), supplemental material).  
In the next step, we used spheroids from high and low cells to compare 
quantitatively the cell collective invasion through of 3D invasion assay. High 
spheroids were clearly more invasive than low spheroids (Figure 32), as much in 
the quantity of spheroids able to invade as in the number of strands per spheroid. 





Figure 32. High βTC4 spheroids presented higher capacity of collective invasion than low βTC4 
spheroids. (A) Representative images of high and low βTC4 spheroids embebbed in Matrigel® 
cultured both under normal conditions of maintenance of βTC4 cells. In the fourth day of culture they 
presented distinct invasion phenotypes. Images at 20X. (B)  Percentage of invasive spheroids in 
relation to a total of spheroids (left graphic). Quantification of strands per spheroid n=20 (righ graphic). 
Difference statically significant (p<0,0001) by Mann-Whitney test.  
To compare an invasion capacity of low and high subpopulations from βTC4 
cells we performed a Transwell® invasion assay in basal condition. βTC4 high and 
low cells (5.0 x 105 cells/mL) of βTC4 DMEM medium (5% of FBS) inserts of the 
Transwell®® containing a polycarbonate membrane were placed. At the bottom 
of the well βTC4 DMEM medium (15% of FBS) was placed.  Cells were maintained 
in normoxia at 21% O2, 5% CO2, 37°C (Figure 33). 
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Figure 33. Experimental design of Transwell® invasion assay to compare an invasion capacity 
of low and high subpopulations from βTC4 cells. 
Finally, as we expect, Transwell® invasion assay confirmed the existence 
of two subpopulations from βTC4 cells with a high differential as for invasion 
capacity (Figure 34).  
 
Figure 34. High βTC4 cells presented greater capacity of invasion in comparison to the low 
βTC4 cells. 500.000 cells were plated onto each well and the assay was performed at 48h. Error bars 
represent S.D, wells/condition n=3. (A) Representative images of hematoxylin staining from βTC4 cells 
in membrain by Transwell®® invasion system: high cells (left image) and low cells (right image). (B) 




βTC4 high cells showed higher invasive capacity than low cells. Difference stastically significant (p< 
0,0001) by Mann-Whitney test. 
In summary, βTC4 in vitro results demonstrated morphological 
characteristics from cancer cell collective invasion and migration. Thus, the high 
and low subpopulations described were applied as tools to confirm the collective 
mechanisms from βTC4 cells and spheroids detailed in the following chapters. 
2. Invasion molecular characterization 
To further validate, previously observed morphological collective Behaviour, 
the next step was to verify molecular evidences of collective invasion in in vitro, in 
vivo samples. 
2.1 Characterization of CDH1-mediated collective invasion  
As mentioned in the introduction section, the CDH1 is a major cell-cell 
adherent molecule that inhibits motility of single cells invasion on matrix. On the 
other hand, CDH1 is an integral component of the guidance mechanisms that 
orchestrate collective movement, given that adhesion between motile cells and 
polar cells holds the cluster together and polarizes each individual cell. Thus, 
knowing the CDH1 role previously described in collective invasion, we decided to 
verify its expression pattern in our samples.  
As we can see in western blot analysis, both untreated and treated tumors 
expressed CDH1, but after treatment tumors slightly increased CDH1 protein 
levels (Figure 35).  In fact, even though western blot analysis is quite efficient for 
determining protein presence or absence in an entire tumor, this technique is not 
able to provide information taking into account protein expression variability in 
different regions of tumor. 
                                                                                                                                             Results 
 
                                                                                                                                    117 
 
Figure 35. RIP1-Tag2 sunitinib treated tumors showed a CDH1 increase levels in relation to 
untreated tumors. Trend of CDH1 increase in sunitinib treated tumors (p=0.0728) by Mann-Whitney 
test. CDH1 detection by western blot from lysates of seven control tumors and seven tumors treated 
during 4 weeks with sunitinib (both 16 weeks of age). α-Tubulin was used as housekeeping gene. Error 
bars represent S.D.  
To verify intratumoral heterogeneity at the CDH1 expression level, we 
performed CDH1 immunohistochemistry staining. Thus, it was possible to 
distinguish CDH1 intensity in periphery key areas, to thereby to correlate protein 
levels with overall tumor invasiveness. Specifically, CDH1 levels were determined 
according with the intensity of CDH1 in each tumor front area, including 
encapsulated tumor fronts and invasive tumor fronts; and excluding tumor center 
areas (Figure 36). Finally, total average of all tumors fronts quantified was 
correlated with the global tumor invasion per each tumor.  
 




Figure 36. CDH1 immunohistochemistry quantification area. Representative images of 
encapsulated tumors (A) and invasive tumors (B). The quantification was performed taking to account 
each tumor front area, including encapsulated tumor fronts (A-B) and invasive tumor fronts (B) 
excluding tumor center areas.  
Since RIP1-Tag2 tumors may be invasive before and after treatment, we 
analysed control and treated tumors in separate according to its invasiveness. As 
shown in Figure 37A, the invasive fronts from RIP1-Tag2 untreated tumors tend 
to present more CDH1 protein levels than encapsulated fronts. Besides that, there 
is a positive correlation between high invasiveness capacity and the increases of 
CDH1 levels (Figure 37B).  
Finally, there almost does not exist CDH1 expression difference between 
invasive and encapsulated tumors in RIP1-Tag2 tumors after sunitinib treatment 
(Figure 37C). As well as, treated tumors which presented no significance when 
correlated with CDH1 expression (Figure 37D). 
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Figure 37. Enrichment of CDH1 protein levels in control invasive tumors. Untreated tumors 
showed a tendency correlation between CDH1 expression and tumor invasion capacity. CDH1 
immunohistochemistry was performed on RIP1-TAG2 tumor tissue at 16 weeks of age, untreated or 
treated with sunitinib during 4 weeks (C=Tumor Center; Ac=Acinar Tissue; TF=Tumor Front). 
Representative images at 20X. (A) Control non-invasive tumor and (B) Control invasive tumor (C) 
Invasive fronts (n=18) showed a trend of increment CDH1 levels in tumor front than encapsulated 
fronts (n=22). (D) CDH1 expression levels in tumor front zones (n=23) were positively correlate with 
high tumor invasion capacity. (E) Sunitinib treated non-invasive tumor. (F) Sunitinib treated invasive 
tumor. (G) CDH1 levels did not change in invasive (n=19) and encapsulated (n=16)  tumor fronts after 
sunitinib treatment. (H) CDH1 expression levels in tumor front zones (n=24) demonstrated a low 
correlation with tumor invasion capacity. Significance was verified by Mann Whitney test. Spearman 
correlations were used to assess associations between continuous variables.  
In the end, to compare these results before and after sunitinib treatment in 
the same analysis, we classified samples by their invasive phenotype, using a 
three-grade nomenclature classification of noninvasive encapsulated islet tumors 
(IT), microinvasive carcinomas (IC1), and widely invasive carcinomas (IC2) as 
described previously (Lopez and Hanahan 2002).  As we can see in Figure 38, 
the only significant difference observed among IT, IC1 and IC2 classified samples, 
was that IT non-invasive control tumors showed lower CDH1 protein levels than 
IC2 widely invasive control tumors.  
 
Figure 38. Control widely invasive tumors (IC2) showed higher CDH1 protein levels than 
noninvasive encapsulated islet tumors (IT), microinvasive carcinomas (IC1).  Not significantly 
differences were observed in sunitinib treated tumors between IT, IC1 and IC2 groups. CDH1 
immunohistochemistry was performed on RIP1-TAG2 tumor tissue at 16 weeks of age, untreated or 
treated with sunitinib for 4 weeks. IT control (n=5), IT sunitinib (n=5); IC1 control (n=16), IC1 sunitinib 
(n=9); and IC2 control (n=2), IC2 sunitinib (n=10). 
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All together, these results showed that despite CDH1 differential found in 
invasive control tumors have been positive, these differences in relation to anti-
angiogenic treated tumors were not observed. Therefore, we conclude that CDH1 
seems to be a major molecule that drives collective invasion in RIP1-TAG2 control 
tumors. However, the mechanisms that promotes tumor collective invasion 
through sunitinib treatment, following unknown and seems guided by CDH1 in 
conjunction with other molecular targets. 
To confirm CDH1 results in βTC4 cells and spheroids, we decided to 
observe CDH1 expression pattern between highly and less invasive cells in our 
2D (Figure 39A) and 3D models (Figure 39B). The results showed that cell and 
spheroids highly invasive express CDH1. While, less invasive cell and spheroids 
demonstrated the absence of the same protein. Thus, the matrix extracellular 





Figure 39. Increase of CDH1 level in βTC4 highly invasive cells and spheroids. (A) Lysates 
prepared with high and low cells from 2D model (n=4). α-Tubulin was used as housekeeping gene. (B) 
Lysates prepared with high and low cells from 3D model (n=2). α-Tubulin was used as housekeeping 
gene.  




Therefore, our highly and less invasive 2D and 3D models were shown to 
be dependent of CDH1 expression to promote invasion effect. These results 
corroborate with our in vivo data, in which CDH1 drives collective invasion in 
control tumors.  
2.2 EMT-related genes in RIP1-Tag2 tumors 
Since the CDH1 results left open the proteins involved in the collective 
invasion after the anti-angiogenic treatment, we decided to investigate other 
possible pathways in this process. For this purpose, a microarray performed by 
Douglas Hanahan from Swiss Institute for Experimental Cancer Research 
(ISREC) in Lausanne was kindly given to us for our project. These data detected 
mRNA expression between two groups. Analysed samples consisted of three 
RIP1-Tag2 tumors untreated and three RIP1-Tag2 tumors sunitinib treated for 4 
weeks. In which the control tumors are associated with low invasiveness 
phenotype and sunitinib treated tumors with high invasiveness phenotype.  To 
determine signatures which could be associated with genetic upregulation or 
downregulation in our different phenotypes, we performed the Gene Set 
Enrichment Analysis (GSEA).   
The Gene-Sets approach is a powerful tool to establish sets of related 
genes or pathways that are functionally associated with a disease phenotype. 
Thus, GSEA was a useful instrument in our case to associate different pathways 
with tumor invasion capacity in RIP1-Tag2 model. The false discovery rate (FDR) 
was used to correct for multiple comparisons and gene set sizes.  We compared 
our RNA sequencing results using different databases available at Molecular 
Signatures DataBase (MolSigDB).  
Interestingly, highlighted the signature defining Epithelial-mesenchymal 
transition (pvalue<0.001) from Hallmark Gene Sets collection (Figure 40A-B), in 
which RIP1-Tag2 tumors untreated were revealed downregulated in this pathway, 
while R2 treated tumor samples was not showed a positive enrichment score in 
all genes analysed (ES) in none genes analysed. Specifically, some genes 
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previously described as pancreatic cancer EMT markers (Beuran et al. 2015)  
such as Vimentin, Fibronectin, Collagen (I) and (III) were also observed to be 
downregulated in treated tumors in sunitinib treated tumors in comparison with 
control tumors (Table 17).  
 
Figure 40. GSEA results demonstrated that control and sunitinib RIP1-Tag2 treated tumors  
were negatively correlated with Hallmark epithelial mesenchymal transition signature. RNA 
expression data obtained was from three control tumors (C1, C2, C3) and  three sunitinib treated 
tumors during four weeks (SU1, SU2, SU3). Significant enrichment of 93 genes in Hallmark epithelial 
mesenchymal transition set was observed. (A) Hallmark epithelial mesenchymal transition enrichment 
plot. Red bars indicate genes expressed preferentially in sunitinib RIP1-TAG2 treated tumors. Purple 
bars indicate genes overexpressed in control tumors. (B) Top 20 leading edge genes in the heat map 
of gene expression from control and sunitinib treated samples corresponding to the Hallmark epithelial 
mesenchymal transition pathway (red: increased expression; blue: decreased expression). 




Table 17. Pancreatic cancer EMT markers enriched on samples from untreated RIP1-TAG2 
tumors compared to sunitinib treated tumors. Relation between RNA levels tumors untreated RIP1-
TAG2 tumors and sunitinib treated tumors in fold change and T-test. 
 
On the other hand, in Canonical Pathways collection, two gene sets 
involving cell junction function presented a high correlation with our data. Results 
from GSEA, showed an upregulation of genes into Reactome Cell-Cell Junction 
Organization (pvalue>0.05) and Reactome Tight Junction Organization 
(pvalue<0.01) signatures in control tumors compared to treated tumors (Figure 
41). 
 
Figure 41. Cell junctions signatures were positively correlated with our data set by GSEA 
analysis.  RNA expression data obtained was from three control tumors (C1, C2, C3) and three 
sunitinib treated tumors for four weeks (SU1, SU2, SU3). In enrichment plots red bars indicate genes 
expressed preferentially in sunitinib RIP1-TAG2 treated tumors. Purple bars indicate genes 
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overexpressed in control tumors. (A) Enrichment plot from Reactome cell cell organization; GSEA 
analysis showed significant enrichment of 16 genes in this signature. (B) Heat map showed the leading 
10 genes that contribute more to the enrichment score. (C) Enrichment plot from Reactome tight 
junction interactions; GSEA analysis showed significant enrichment of 12 genes in this signature. (D) 
Heat map showed the leading 10 genes that contribute more to the enrichment score 
Collectively, highly invasive RIP1-Tag2 tumors post-treatment decrease 
EMT related genes expression and increase gene expression of proteins 
associated with cell-cell binding function. In addition, there is a tendency of 
increases CDH1 level in untreated invasive tumors. However, the relation between 
CDH1 and invasiveness was not completely confirmed in RIP1-Tag2 treated 
tumors.  
3. Collective invasion candidates 
3.1 Barrier claudins as collective proinvasion markers in RIP1-
Tag2 tumors 
The results obtained guided us to the hypothesis that other molecular 
mechanisms act together with CDH1 in PanNETs cell collective Behaviour. Thus, 
following steps were focalized in validate the differential expression of candidates 
collective invasion marker in in vitro high and low βTC4 spheroids (2D, 3D), in vivo 
RIP1-Tag2 model before and after the anti-angiogenic treatment and clinical data 
from non-malignant primary tumor, malignant primary tumor and metastasis. 
To describe other molecules able to orchestrating RIP1-Tag2 tumor 
collective invasion, we used GSEA analysis data previously described by 
Microarray technique. As mentioned earlier, were compared RNA data from three 
control tumors and three sunitinib treated tumors. Since control tumors are related 
as lower invasive and sunitinib treated tumors as highly invasive, the invasive 
phenotype demonstrated to be positively correlated (pvalue<0.01) with genes from 
tight junctions pathway (Figure 42A). Indeed, 12 genes from reactome tight 
junction interactions presented a positive GSEA core enrichment.  Specifically, 




mainly genes from claudin family showed upregulated in tumors with high invasion 
capacity (Figure 42B). 
 
Figure 42. Leading edge subsets of genes that contributed most to the enrichment score in 
Reactome tight junction interactions transition pathway are composed mainly by claudins 
members family. (A) Enrichment plot from Reactome tight junction interations.  (B) Table of genes 
enriched in samples from sunitinib treated tumors compared to untreated RIP1-TAG2 tumors. 
Claudins are membrane proteins found in tight junctions. According to the 
functional definition previously described, claudins protein can be generally 
classified in two groups: barrier-forming or pore-forming. Barrier-forming, are 
those that predominantly increase transepithelial resistance (TER) or decrease 
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solute permeability. The second group, pore-forming, are those that predominantly 
decrease TER or increase solute permeability (Günzel and Yu 2013; Baumgartner 
et al. 2017) (Table 18). Using this classification, we verified claudin RNA 
expression levels according their functional role in RIP1-Tag2 tumors untreated 
and sunitinib treated. 
 Table 18. Claudins isoforms according their functional permeability characteristics. 
 
Strikingly, when we compared the average RNA expression from barrier-
forming claudins (Cldn1, Cldn3, Cldn4, Cldn5, Cldn6, Cldn8, Cldn9, Cldn11, 
Cldn14, Cldn18, Cldn19) with pore claudins (Cldn2, Cldn10, Cldn15, Cldn17)  
higher expression levels of barrier-forming claudins were found than pore-forming 
claudins in all tumors independent of the treatment applied (Figure 43). It is to be 
noted that this analysis was performed excluding Claudin-7 results, given that its 
function does not well establish between pore and barrier role.    





Figure 43. Barrier-forming claudins stood out in RIP1-TAG2 tumors. RNA average expression 
from barrier-forming claudins (Cldn1, Cldn3, Cldn4, Cldn5, Cldn6, Cldn8, Cldn9, Cldn11, Cldn14, 
Cldn18, Cldn19) is higher than pore-forming (Cldn2, Cldn10, Cldn15, Cldn17) claudins before and after 
anti-angiogenic treatment. Error bars represent S.D. Difference statically significant (p<0,0001) by 
Mann-Whitney test.  
In order to decipher whether the anti-angiogenic treatment affect the 
claudins pattern expressed, we decided taking into account claudin expression 
differences between untreated and sunitinib treated tumors. To this aim, we 
checked claudin fuctions from the leading edge genes determined by GSEA 
analysis.  
Among the most enriched genes in tumors treated with sunitinib in respect 
to the control tumors are: (41.68%) barrier-claudins, (16.66%) pore-claudins, 
(16.66%) claudins without well-defined function and, (25%) other molecules that 
are not part of the claudin family. Therefore, the barrier claudin represent almost 
half of the leading edge genes enriched in treated tumors (Figure 23).  
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Figure 44.  Barrier-claudins forming group represented almost half of leading edge genes 
enriched in treated tumors. Leading edge genes determined by GSEA analysis were divided by 
groups: (41.68%) barrier-claudins, (16.66%) pore-claudins, (16.66%) claudins without well-defined 
function and, (25%) other molecules. Percentage of genes was calculated considering the 12 genes 
from Reactome tight junction interactions that presented a positive GSEA core enrichment. 
Overall, these data suggests that barrier-claudins should play an important 
role in both RIP1-Tag2 tumors before and after anti-angiogenic treatment. Thus, 
we hypothesize that barrier-forming claudins could be part of mechanisms 
responsible to collective invasion observed in RIP1-Tag2 tumors. To determine, 
which more relevant barrier-forming claudins in this context, we compared 
expression differential between untreated and sunitinib treated tumors for each 
barrier-forming claudin (Figure 45).  
 
Figure 45. Cldn4 showed the most difference between untreated and sunitinib treated RIP1-
TAG2 tumors in terms of RNA levels. Barrier-forming claudins RNA differential levels (Sunitinib 
treated tumors – Control tumors) of leading edge genes from GSEA analysis.  




As a result, we found that Cldn4 is the most differentially expressed gene in 
high invasive tumors treated with sunitinib. To investigate the CLDN4 role in tumor 
malignancy, the next step was to validate the RNA results also on the protein level. 
3.2 CLDN4 expression validation in RIP1-Tag2 tumors 
Since CLDN4 was identified as a possible collective invasion marker in 
RIP1-Tag2 tumors, we decided to elucidate its protein expression through protein 
level intensity, intratumoral localization and finally by RNA levels.  When we 
compared, eight untreated tumors and eight sunitinib treated tumors, we found 
that the CLDN4 intensity increases significantly when animals RIP1-Tag2 were 
treated with sunitinib for 4 weeks (Figure 46).  
 
Figure 46. Increase in CLDN4 expression in RIP1-Tag2 tumors treated with sunitinib. CLDN4 
detection by western blot from lysates of seven control tumors and seven tumors treated during 4 
weeks with sunitinib (both 16 weeks of age). α-Tubulin was used as housekeeping gene. Error bars 
represent S.D. Difference stastistically significant (p<0,0001) by Mann-Whitney test.  
During CLDN4 validation, we also verified CLDN4 levels in RIP1-Tag2 
animals treated with DC101 and controls. DC101 is an anti-angiogenic treatment 
(Anti-VEGFR2 blocking antibody) in which previous findings from our group 
showed beneficial short-term effects in RIP1-Tag2 tumors.  
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However, animals DC101 treated after consecutive weeks presented an 
adaptive resistance that promotes increased local invasion (section 6.1). Our 
findings demonstrated a relation between DC101 anti-angiogenic treatment and 
an intensity increase of CLDN4 levels in relation to untreated animals (Figure 47). 
 
Figure 47. Increase in CLDN4 expression in RIP1-TAG2 tumors treated with DC101. CLDN4 
detection by western blot from lysates of seven control tumors and seven tumors treated during 4 
weeks with DC101 (both 16 weeks of age). α-Tubulin was used as housekeeping gene. Error bars 
represent S.D.  
To localize the expression of CLDN4 in RIP1-Tag2 tumors, we performed 
an immunohistochemistry assay in control and sunitinib treated tumor samples. 
The immunohistochemistry staining showed clear intratumoral heterogeneity of 
CLDN4 expression pattern, so, this protein did not distribute in all tumor zones 
with the same intensity. Consequently, CLDN4 quantification was performed 
taking to account three tumor zones, (i) invasive tumor front, (ii) encapsulated 
tumor front, and (iii) tumor center. The CLDN4 immunohistochemistry 
quantification method was similarly to applied to CDH1 (Figure 15), however, in 
this case, including tumor center areas. 




Notably, RIP1-Tag2 tumors before anti-angiogenic treatment demonstrated 
a CLDN4 expression increases in invasive front in relation to the center zone 
(Figure 48A).  In addition, was verified a correlation between the high tumor 
invasion capacity and the increase CLDN4 protein expression (Figure 48B). B). 
Regarding the tumor after anti-angiogenic treatment, sunitinib tumors treated 
showed significantly more CLDN4 intensity on the invasive fronts than on the 
encapsulated fronts and tumor center (Figure 48C). Furthermore, these tumors 
conferred a high tendency to correlate the global invasion capacity and CLDN4 
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Figure 48. CLDN4 as an invasion marker in RIP1-TAG2 tumors before and after the anti-
angiogenic treatment. Immunohistochemistry was performed on RIP1-TAG2 tumor tissue at 16 
weeks of age, untreated or treated with sunitinib for 4 weeks (C=Tumor Center; Ac=Acinar Tissue; 
TF=Tumor Front). Representative images at 20X. Significance was verified by Mann Whitney test. 
Spearman correlations were used to assess associations between continuous variables.  (A) Control 
non-invasive tumor and (B) Control invasive tumor. (C) Invasive fronts (n=22) showed more CLDN4 
levels in periphery than tumor center (n=20) (D) CLDN4 expression levels center and periphery tumor 
zones (n=24) were highly correlated with high tumor invasion capacity. (E) Sunitinib treated non-
invasive tumor. (F) Sunitinib treated invasive tumor. (G) CLDN4 protein levels in invasive tumor fronts 
(n=33) was higher than encapsulated tumors (n=23) and tumor center (n=26) (B) Sunitinib treated 
RIP1-TAG2 tumors presented positive correlation almost significantly between the expression of 
CLDN4 and global high tumor invasion capacity (n=27).   
In the next step, tumors were classified according to their invasion capability 
as IT, IC1 and IC2, and CLDN4 intensity levels was determined per tumor. The 
results demonstrated an increase in CLDN4 expression in highly invasive tumors 
in both, control and sunitinib treated tumors. However, no significant differences 
were observed to be determined only by the treatment and independent of the 
invasion capacity (Figure 49). These data indicate that CLDN4 is one of the main 
protein that acts in collective invasion in RIP1-Tag2 tumors before and after the 
anti-angiogenic treatment.  
 
Figure 49. Both control tumors and sunitinib treated tumors increased CLDN4 levels in widely 
invasive tumors (IC2). CLDN4 immunohistochemistry was performed on RIP1-TAG2 tumor tissue at 
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16 weeks of age, untreated or treated with sunitinib for 4 weeks. IT control (n=3), IT sunitinib (n=2); 
IC1 control (n=16), IC1 sunitinib (n=16); and IC2 control (n=6), IC2 sunitinib (n=9) 
Finally, these results were confirmed by RNA levels. Then, results obtained 
by Taqman® Real-Time PCR from RIP1-Tag2 tumors data revealed low Cldn4 
levels in control samples. Interestingly, all tumors after anti-angiogenic treatment 
increased Cldn4 expression on at least seven times in relation to control tumors 
(Figure 50). These results demonstrated that this increase of Cldn4 expression in 
RIP1-Tag2 tumors occurs at the translational level. 
 
Figure 50. Sunitinib and DC101 anti-angiogenic treatments leaded an increase RNA expression 
of Cldn4 in RIP1-Tag2 tumors.  Results obtained from Taqman® Real-time PCR of two control tumors 
and two tumors treated for 4 weeks with sunitinib or DC101 (both 16 weeks of age). RNA quantification 
of Cldn4 was normalized by β-actin measured by 2^-ΔCT. (A) RNA expression level of RIP1-Tag2 
tumors untreated (n=2), treated with sunitinib (n=2) and treated with DC101 (n=2). 
Altogether, these results confirmed an increase Cldn4 RNA and protein 
levels in highly invasive tumors. In addition, CLDN4 protein was found located on 
the invasive tumor fronts, whether controls or treated. Due to these encouraging 
results, the next step was to verify CLDN4 presence in our in vitro models for later 
CLDN4 modulation on functional assays.  




3.3 Barrier claudins in βTC4 2D and 3D model in vitro model  
In order to verify in vitro CLDN4 presence in βTC4 cells in 2D model we 
performed the western blot technique. In fact, we were surprised with not 
expression of CLDN4 in both high and low βTC4 cells (Figure 51A). Additionally, 
results from immunofluorescence confirmed CLDN4 absent expression in these 
cells.  It is worth mentioning, that high cells showed higher levels of CLDN4 than 
low cells, but even so the CLDN4 levels in both cases were almost nonexistent 
(Figure 51B).  
 
   
 
Figure 51. CLDN4 protein could not be detected in any of βTC4 cell subpopulations. (A)  Western 
blot of CLDN4 protein from lysates of the high and low βTC4 cells in 2D model under normal conditions 
of βTC4 cells culture. α-Tubulin was used as housekeeping gene. (B) Immunocytofluorescence of 
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CLDN4 in high  and low  βTC4 cells (2D model) under normal conditions of  βTC4 cells culture. SN12C 
from renal cell carcinoma was used as positive control of CLDN4. Images at 40X.  
It is well known that not all molecules are represented equally in the cells 
and tumors that originated them, due a microenvironment changes that these cells 
undergo. This fact has spurred the generation of new 3D culturing techniques that 
more closely reflect the features of the primary tumors from which they were 
derived. For this purpose, we analysed CLDN4 protein level in 3D culture. 
However, high and low βTC4 spheroids also did not present this protein in three-
dimensional architecture (Figure 52). 
 
Figure 52. Absence of CLDN4 protein level was verified in high and low βTC4 spheroids. CLDN4 
detection by western blot from two lysates of high and low ΒTC4 spheroids in2D model cultured for 3 
days in normal βTC4 conditions culture. RIP1-Tag2 control tumor was used as a positive control for 
CLDN4 protein. 
Finally, spheroids βTC4 in 3D conditions were analysed by a Taqman® 
assay aiming its high RNA levels detection capacity. We noted that both, high and 
low subpopulations showed insignificant values in comparison to Cldn4 positive 
control represented by RIP1-Tag2 tumor (Figure 53A).  
A possible explanation for such a low level of CLDN4 would be that in our 
in vivo model CLDN4 induction was observed in RIP1-Tag2 tumors after anti-
angiogenic treatment. Thus, we decided to mimic the anti-angiogenic treatment in 
vitro through hypoxia 10% to induce Cldn4 expression. However, this approach 
was not efficient to promote Cldn4 expression (Figure 53B). 





Figure 53. There was almost no relative Cldn4 expression in high and low βTC4 spheroids in 
3D model. Hypoxia conditions did not induce a CLDN4 expression.  Results obtained from a Taqman® 
Real-time PCR, normalized by -actin and measured by 2^-dCT. Error bars represent S.D. RIP1-Tag2 
control tumor was used as a positive control for Cldn4 expression. (A) RNA quantification performed 
with high and low βTC4 spheroids in 3D model after three day of invasion.  (B) RNA quantification 
performed with high βTC4 in 3D model after 24h of hypoxia 10% condition (n=2). 
Owing to these results, we tested in 2D model more rigorous treatments to 
promote CLDN4 induction in βTC4 cells. We combined different hypoxia levels 
with nutrient deprivation in terms of medium dilution and FBS reduction (Table 19) 
and CLDN4 expression was verified by western blot. Finally, these treatments 
applied were not able to induce CLDN4 either. 
Table 19. CLDN4 induction treatments 
 
For the purpose of verification of the possibility that βTC4 cells had lost the 
CLDN4 expression during its in vitro culture, we tested different βTC cell primary 
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lines with few passages (5-7), developed by our group from distinct RIP1-Tag2 
tumors. As we showed in Figure 54, none of the primary βTC cells demonstrated 
the CLDN4 expression. 
These results demonstrated that CLDN4 absence in vitro is a common 
characteristic among the four primary lines cultured obtained from different RIP1-
Tag2 tumors. Interestingly, as we can see in previous analyses, most of in vivo 
RIP1-Tag2 tumors are CLDN4 positive, even though in low intensity. Thus, our 
results indicated that there is a loss of CLDN4 when we move from in vivo to in 
vitro system.  
 
Figure 54. Absence of CLDN4 protein was verified in primary lines from RIP1-Tag2 tumors. 
Western blot of CLDN4 protein from lysates of three different βTC cell primary lines developed by our 
group. RIP1-Tag2 tumors were used as CLDN4 positive controls. α-Tubulin was used as housekeeping 
gene. 
Considering that we were not able to detect CLDN4 in any approaches used 
in our in vitro model, we decided to elucidate which barrier-forming claudins, apart 
from CLDN4, could be acting in βTC4 cell invasion process. In this way, was 
performed a screening of the presence of barrier-forming claudins in βTC4 cells 
by western blot technique.  
Among all claudins verified (data not shown), CLDN1 was found expressed 
in high cells and almost not expressed in low cells (Figure 55A-B). These results 
were also validated by immunofluorescence. The immunofluorescence images 
make us speculate that the leader migratory cells are the ones that most present 
CLDN1 (Figure 55C white arrows). 






Figure 55. Increase in CLDN1 protein level was detected in highly invasive phenotype of βTC4 
cells. (A) CLDN1 detection by western blot from two lysates of high and low βTC4 cells in 2D model 
in normal βTC4 conditions culture. (B) Western blot quantification by relative intensity. α-Tubulin was 
used as a housekeeping gene. Error bars represent S.D. (C) Immunocytofluorescence of CLDN1 
protein in βTC4 high and low cells in 2D model (40X). Leader migrating cells seems express high levels 
of CLDN1 (white arrows).  Ren13 cells were used as control of CLDN1 protein expression. 
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To confirm ECM's role in relation to CLDN1 expression in βTC4 spheroids, 
we verified this protein in 2D and 3D models using high and low spheroids. 
Interestingly, low spheroids that in 2D showed very low levels of CLDN1 when in 
3D model acquired this protein without change CDH1 levels. Thus, low spheroids 
seem to recruit CLDN1 in presence ECM, when spheroids are embedded in three-
dimensional culture environment to promote their invasion (low levels) without the 
help of CDH1 (Figure 56).   
 
Figure 56. The three-dimensional culture environment increased CLDN1 levels in low βTC4 
spheroids. CLDN1 and CDH1 detection by western blot from two lysates of high and low βTC4 
cells/spheroids in 2D model and 3D model at normal conditions of culture. βTC4 spheroids were 
incubated in three-dimensional culture (Matrigel®) for 3 days and after was generated a lysate. α-
Tubulin was used as housekeeping gene. 
To further describe the barrier claudins role in in vitro and in vivo model, we 
decided to compare both samples in a single analysis. For this, we verified the 
protein level in high and low βTC4 cells and RIP1-Tag2 tumors untreated and 
sunitinib treated.  
As expected, βTC4 cells showed, again, an absence of CLDN4, while RIP1-
Tag2 untreated and treated tumors expressed CLDN4. However, highly invasive 
treated tumors had increased CLDN4 levels (Figure 57A). 
On the other hand, CLDN1 protein was not detected untreated and treated 
tumors, its presence was verified only in βTC4 cells. It is important to highlight the 
high differential observed between high and low subpopulations, in which the high 




invasive phenotype showed higher CLDN1 expression level than low invasive 
phenotype (Figure 57B).  
 
Figure 57. Claudin1/4 barrier-forming as collective invasion mechanism in RIP1-Tag2 tumors 
and βTC4 cells. Western blot from lisates of high/low TC4 cells 2D model, and untreated/treated 
RIP1-Tag2 tumors, two per condition. (A) Invasive tumors from RIP1-TAG2 increase CLDN4 levels. 
CLDN4 protein was not detected in βTC4 cells. (B) Highly invasive cells showed higher expression of 
CLDN1 than low invasive cells. None of the RIP1-Tag2 tumors presented CLDN1 protein expression. 
(C) Western blot quantification by relative intensity. α-Tubulin was used as housekeeping gene. Error 
bars represent S.D. Graphics demonstrated an barrier-claudins proteins switch that occurs in PanNETs 
in vitro and in vivo model.  
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Altogether, these results indicate that, CLDN1 and CLDN4 barrier claudins 
suffer a molecular switch between them in our in vitro and in vivo models. 
Specifically, CLDN1 acts in βTC4 model and CLDN4 in RIP-Tag2 model, being 
that both are more express according with the tumoral invasiveness increase. 
Moreover, both proteins perform the same sealing function, maintaining cell-cell 
junction dynamic integrity allowing the cell collective invasion, during the invasion 
process in βTC4 cells and RIP-Tag2 tumors (Figure 58). 
 
Figure 58.  Molecular switch of barrier claudins (1/4) in our in vivo and in vitro model. Schema 
detailing the CLDN4 presence in neuroendocrine tumors from RIP1-Tag2 pancreas (left side). As well 
as, CLDN1 existence in βTC4 cells derived of RIP1-Tag2 tumor, after undergoing culture in vitro (right 
side). Finally, although CLDN1 and CLDN4 being different proteins, both show the same barrier 
function, capable of sealing two neighboring cells. 
 




4. CLDN1 functional in vitro validation  
4.1 CLDN1 expression in βTC4 cells exposed to hypoxia and lack 
of nutrients effects 
Previous results demonstrated that anti-angiogenic treatment efficiently 
decreases the number of tumor vessels essential for the delivery of nutrients and 
oxygen required for tumor cells proliferation. However, it does not prevent tumor 
progression, and further, increases of invasion capacity (as described in 
introduction section).  
Therefore, we hypothesized that βTC4 cells sense this “inhospitable 
environment” and, after a period of adaptation, could be respond up-regulating 
CLDN1 and increasing their invasion capability. As unfortunately, anti-angiogenics 
don’t target directly tumor cells, we mimicked the anti-angiogenic treatment mixing 
different treatments involving: hypoxia (3% and 10%), nutrient deprivation and 
variations in fetal bovine serum concentration.  
Then, in this sense, we chose to repeat exactly the same methodologies 
applied to promote CLDN4 induction to try induce CLDN1 (Table 19). Among all 
treatments, we observed a clear CLDN1 induction when βTC4 cells were treated 
for 2 previous days with nutrient deprivation and the last 24 hours with hypoxia 
10% (Figure 59C).  
Therefore, cells exposed to hypoxia, when treated with lack of nutrients 
responded by up-regulating CLDN1 protein levels (Figure 59A-B). 
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Figure 59. CLDN1 overexpression was observed on βTC4 cells under conditions of hypoxia and 
nutrient deprivation. (A) CLDN1 detection by western blot from two lysates of low βTC4 cells in 
normal βTC4 conditions culture, βTC4 cells in hypoxia 10% and βTC4 cells in hypoxia 10% plus 
nutrient deprivation. (B) Western blot quantification by relative intensity. α-Tubulin was used as 
housekeeping gene. Error bars represent S.D. (C) Illustration of anti-angiogenic mimic treatment able 
to induce CLDN1. 
 




CLDN1 is functionally associated with cell-cell contact and the maintenance 
of cellular polarity. However, the mechanisms driving claudin-mediated cancer 
invasion and migration remain poorly understood.  
Altered expression of CLDN1 protein has been detected in various steps of 
cancer progression. CLDN1 upregulation was described in colorectal, melanoma, 
breast, cervical and gastric cancer, while in lung, prostate, gastric, breast and 
colorectal cancer CLDN1 was verified as downregulated (Kwon 2013; Tabariès 
and Siegel 2017). 
To determine the possible function of CLDN1 up-regulation in PanNETs 
invasion as a consequence of oxygen and nutrient deprivation, we analysed its 
effect by Transwell® invasion assay in three conditions: 
a) Control cells in βTC4 DMEM medium (15% FBS). 
b) Hypoxia 10% treatment in βTC4 DMEM medium (15% FBS). 
c) Hypoxia 10% treatment in βTC4 DMEM medium (15% FBS) diluted 
at 50% in PBS.  
 Thus, βTC4 high cells (5.0 x 105 cells/mL) were plated in conditioned 
medium βTC4 medium deprived for 24 hours (a-b) conditions, or conditioned 
medium βTC4 medium diluted in 50% conditions (A). All cells were maintained in 
normoxia conditions at 21% O2, 5% CO2, 37°C for the next 24 hours. After, (b) 
and (c) conditions were transferred to a hypoxia chamber at 10% O2, 5% CO2, 
37°C and incubated the last 24 hours (Figure 60). Thus, totalizing 48 hours of 
Transwell® assay. 
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Figure 60.  Experimental design of Transwell® invasion assay to verify the CLDN1 induction 
effects by lack of nutrients and hypoxia 10%. 
Obtained results confirmed the relation between the over expression of our 
candidate and the higher βTC4 cells invasion capacity. Specifically, we reported 
that only hypoxia conditions were not able to increase the invasion capacity and 
CLDN1 expression. However, when we combined hypoxia conditions with nutrient 
reduction, we were able to mimic anti-angiogenic treatment effects in terms of 
invasion capacity and CLDN1 expression (Figure 61).   
It is to be noted that βTC4 cells, even if in normal conditions culture, already 
have a high invasiveness. Knowing that, these cells are of delicate maintenance, 
the aggressive culture conditions promote, in a first moment, loss of βTC4 invasion 
capacity. 
However, our findings suggest that, if this aggressive treatment is sufficient 
to mimic anti-angiogenic treatment and overexpress CLDN1, as in the case of 
hypoxia added to nutrient deprivation, βTC4 cells rescue their invasion capability, 
being significantly more invasive than only hypoxia treated cells where there is no 
overexpression of CLDN1.  
  





Figure 61. Hypoxia and lack of nutrients drove CLDN1 upregulation and promoted an increase 
invasion capacity in βTC4 cells after treatment.  500.000 cells were plated onto each well and the 
assay was performed at 48h. Error bars represent S.D, wells/condition n=3. (A) Representative images 
of hematoxylin staining from βTC4 cells in membrane by Transwell® system. (B) βTC4 cells in hypoxia 
10% plus nutrient deprivation showed higher invasive capacity than βTC4 cells only hypoxia 10%. 
Difference statically significant (p< 0,0001) by Mann-Whitney test.  
To summarize, βTC4 cells in conditions that mimic anti-angiogenic 
treatment demonstrated a functional direct relation between CLDN1 expression 
and βTC4 cells invasion process.   
4.2 CLDN1 in vitro inhibition 
4.2.1 Effects of CLDN1 inhibition of βTC4 cells in 2D model 
Once known the ability of βTC4 cells to respond to the anti-angiogenic 
treatment effects in vitro, the YM201636 inhibitor was used to determine the in 
vitro consequences of CLDN1 inhibition.  
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YM201636 is a small molecule inhibitor of PIKfyve. The enzyme PIKfyve is 
a lipid kinase (240kDa) responsible to phosphorylates the D-5 position in 
endosomal phosphatidylinositol-3-phosphate (PI3P) to yield the 3,5-bisphosphate 
(PI(3,5)P2). This kinase binds to PI(3)P via its FYVE domain. PIKfyve is critical for 
maintaining the proper morphology of the endosome/lysosome. Thus, this enzyme 
has been implicated in processes as autophagy and endosome to trans-Golgi 
network trafficking (Cai et al. 2013). Pikfyve inhibition by YM201636 consequently 
blocks constant recycling of CLDN1, which decrease its level in membrane and 
accumulates intracellularly. Even that, YM201636 inhibited also CLDN2 for being 
recycled in a similar way to CLDN1, the localization of others epithelial markers as 
ZO-1, occludin and CDH1 appear unchanged (Dukes, Whitley, and Chalmers 
2012). 
First, we verified phenotype and viability changes of βTC4 cells under 
YM201636 treatment. Phenotypically, these βTC4 cells remain unchanged after 
YM201636 treatment (Figure 62A), this conclusion can be best observed in 
greater resolution in Figure 62B-C. As to cell viability, visually we did not observe 
differences between control and YM201636 treated cells, this viability 












Figure 62. YM201636 treatment did not change the cell phenotype and viability. βTC4 cells were 
plated and treated with YM201636 (400nM) for 24 hours. (A) Pictures at 10X. (B-C) Pictures at 40X. 
(D) Percentage of cell viability by trypan blue staining. 
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To assess CLDN1 inhibition functional effects, YM201636 inhibitor was 
added to βTC4 media and invasive capacity of cells was measure by Transwell® 
invasion assay. In detail βTC4 high cells (5.0 x 105 cells/mL) in βTC4 DMEM 
medium (5% of FBS) were placed in inserts of the Transwell®. At the same time, 
the inhibitory effect was studied by adding 400nM of CLDN1 inhibitor (YM201636), 
to the upper compartment of the Transwell® (Figure 63). At the bottom of the well 
βTC4 DMEM medium (15% of FBS) was placed.  Cells were maintained in 
normoxia at 21% O2, 5% CO2, 37°C for 24 hours.  
 
Figure 63.  Experimental design of Transwell® invasion assay to assess invasion capacity 
effect by CLDN1 inhibition using YM201636. 
βTC4 cells responded to YM201636 inhibitor stimulation in vitro by 
decreasing their invasion to almost 40% (Figure 64).  





Figure 64. CLDN1 inhibition drastically decreased the invasion abilities of βTC4 cells. (A) 
Representative images (20X) of Transwell® membranes hematoxylin stained from cells treated with 
vehicle and YM201636. (B) Quantification of invading cells through Transwell® Matrigel®® 
membranes in 24 hours. Difference statically significant (p< 0,0001) by Mann-Whitney test. Error bars 
represent S.D, wells/condition n=3. 
Taking into account the microenvironment closest to what occurs in the 
tumor in vivo and to confirm this invasion as collective invasive, we decided to 
verify CLDN1 inhibition by YM201636 treatment in 3D model of βTC4 spheroids 
submerged in Matrigel®. 
In 3D model, results confirmed a drastic decrease of βTC4 spheroid 
invasion capacity when inhibiting CLDN1, consistent with the effects observed with 
its inhibition in βTC4 cells in 2D model. Specifically, the number of strands per 
spheroid is halved when the spheroids are treated with YM201636, this effect 
occurs since the first day staying until the third and last day of the treatment 
(Figure 65). 
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Figure 65. βTC4 spheroids treated with YM201636 responded to CLDN1 inhibition decreasing 
their invasive capacity.  βTC4 spheroids were submerged in 3D Matrigel® structure and treated with 
YM201636 (400nM) at day 0. (A) Pictures of the same spheroid at 20X were taken in 0, 1, 3 day of 
treatment. (B-C) Global final differences observed in pictures of different spheroids at day 3 were 
performed at 10X objective. (D) Number of strands per spheroids for all the days of the assay.  (E-F) 
Strands capable to invade the Matrigel® from vehicle conditions (n=83) and YM201636 treated (n=92) 
were quantified per spheroid at day 1 (E) and day 3 (F). Difference statically significant (p< 0,0001) by 
Mann-Whitney test. Error bars represent S.D. 
Altogether, results from these functional assays, demonstrated that CLDN1 
inhibition clearly caused decreased βTC4 cells and spheroid invasion while 
CLDN1 induction via anti-angiogenic effects promoted increased βTC4 cells 




invasion. These results support our hypothesis that barrier claudin, CLDN1, is one 
of the most factors responsible for collective invasion in PanNETs.  
Therefore, our data demonstrated both in vitro functional implications and 
in vivo an association of the claudin family in establishing the malignization 
process before and after the anti-angiogenic treatment in RIP1-Tag2 PNET mouse 
model. 
5. Clinical relevance in PanNETs patients 
Overall, our results have demonstrated both in vitro and in vivo association 
between barrier-claudins, specifically CLDN1/4, and tumor malignization. In order 
to move these results to clinical setting we performed an analysis of an 
independent gene expression study of a set of mRNA transcriptomes of PanNET 
patients from the public database Gene Expression Omnibus (GEO) reference  
GSE73338 (Missiaglia et al. 2009). 
Patient dataset analysed comprised 90 samples of a PanNET study 
containing normal pancreas, normal pancreas islets, primary non-functional 
tumors, primary functional tumors (insulinomas), and metastases from non-
functional primary tumors (Figure 66; graphic on top). To correlate these data 
according tumor malignization steps, clinical data from PanNETs was grouped in 
three progression stages, primary non-malignant tumors, primary malignant 
tumors and metastasis.  
In total the analysis was performed using 63 non-functional primary tumors, 
in which 31 had synchronic metastasis and were determined as malignant primary 
tumors. In this group of 31 patients, 7 samples were from liver or lymph node 
metastases. Finally, the 26 non-functional primary tumor patients did not have 
metastasis were classified as non-malignant primary tumors (Figure 66; graphic 
below) (Missiaglia et al. 2009; Sadanandam et al. 2015). 
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Figure 66. PanNET patient samples dataset description. Graphical description of the GSE73338.  
PanNET patient dataset as described in Missiaglia et al., 2009 . Clinical dataset is comprise by 97 total 
samples, being 4 normal pancreas islet (4%) (used as control tissue), 7 metastases (8%), 62 
insulinoma primary tumors (69%) and 19 non-functional tumors analysis (19%) (further divided into 26 
non-malignant and 31 malignant samples).  
5.1 EMT-related genes in patient samples   
To better extrapolate the data obtained in RIP1-Tag2 mice, we chose to 
select only data from primary non-functional tumors. These tumors are often 
classified according to the WHO as high-grade tumors. High grade tumors are 
characterized as more aggressive and proliferative tumors, which happen to be 
more similar to RIP1-Tag2 invasive mice tumors. However primary non-functional 
tumors do not secrete insulin as RIP1-Tag2 mice tumors do.  
To understand to what extent this correlation observed can be traced to 
tumor malignancy, we performed a detailed analysis relating our tumor invasion 




markers with different stages of tumor malignancy. Then, clinical data from 
PanNETs were grouped in three progression stages, primary non-malignant 
tumors, primary malignant tumors and metastasis. In total, the analysis was 
performed using 57 non-functional primary tumors, in which 31 had synchronic 
metastasis and were determined as malignant primary tumors. In this group of 31 
patients, 7 samples were from liver or lymph node metastases. Finally, the 26 non-
functional primary tumor patients did not have metastasis were classified as non-
malignant primary tumors.  
Taking in account our previous results, in which we did not found EMT 
expression patterns in vitro and in vivo samples, we decided to confirm these 
findings in PanNETs clinical data. To this aim, EMT related genes in pancreatic 
cancer (Beuran et al. 2015) were individually analysed in non-malignant primary 
tumors, malignant primary tumors.  
RNA levels from genes described as attenuated and acquired during in EMT 
process as Fibronectin (Fn1), Integrin Subunit Alpha 5 (Itga5), Syndecan 1(Sdc1), 
Zinc Finger E-Box Binding 2 (Zeb2), Snail Transcriptional Repressor 1(Snai1) and 
Transforming Growth Factor Beta 1 (Tgfb1) were verified in the three stages of 
tumor progression. 
 In this analysis, we not found any clear expression changes in these EMT 
markers in non-malignant primary tumor, malignant primary tumor and metastasis. 
In addition, Cdh1 downregulation considered determinant as mesenchymal 
phenotype marker in our data was not observed.  Unlike this, Cdh1 was found 
upregulated in metastasis in relation to malignant primary tumor (Figure 67).  
Thus, these consistently clinical results demonstrated that the 
mesenchymal phenotype is not the main mechanism that promote PanNETs 
tumors malignancy in patients, instead of this, is collective invasion that seems 
has this role. 
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Figure 67. Clinical samples did not show differences in expression levels in the most of EMT 
related genes during tumor progression. (A-H) RNA levels from EMT related genes in patients 
samples of non-malignant tumors (n=26), primary malignant tumors (n=31) and metastasis (n=7) were 
compared. (A) Differences were statistically significant as to CDH1 levels by Mann-Whitney test, being 
p=0.0561 in malignant tumors primary versus metastases. Error bars represent S.D 
5.2 Expression of barrier-forming claudins in clinical samples  
Finally, seeking to understand a claudin family role in PanNETs patient 
samples, were compared all barrier and pore forming claudin RNA levels in clinical 
samples independently of malignancy. We confirmed higher levels of barrier-




forming claudins than pore-forming claudins in PanNETs tumors from patients 
(Figure 68). 
 
Figure 68.  PanNETs patient samples showed higher levels of barrier-forming claudins in 
comparison to pore-forming claudins. RNA average expression from barrier-forming claudins 
(CLDN1, CLDN3, CLDN4, CLDN5, CLDN11, CLDN14, CLDN18) is higher than pore-forming (CLDN2, 
CLDN10, CLDN15, CLDN17) in primary non-malignant tumors and primary malignant tumors 
(p=0.0014). Error bars represent S.D. Difference statically significant by Mann-Whitney test. 
As well as, malignant tumors increase a barrier-forming claudins expression 
in comparison to non-malignant tumors (Figure 69A). In addition, the barrier 
claudins difference values between malignant and non-malignant tumors 
demonstrated that CLDN1 and CLDN4 are among the three barrier claudins most 
differentially expressed in malignant tumors (Figure 69B).  
                                                                                                                                             Results 
 
                                                                                                                                    159 
 
Figure 69.  Primary malignant tumors from clinical samples did show high expression of barrier-
forming claudins. (A) RNA average expression from barrier-forming claudins (CLDN1, CLDN3, 
CLDN4, CLDN5, CLDN11, CLDN14, CLDN18) in primary malignant tumors versus primary non-
malignant tumors). Primary malignant tumors increase a barrier-forming claudin levels in comparison 
to primary non-malignant tumors (p = 0.0118). Error bars represent S.D. Difference statically significant 
by Mann-Whitney test. (B) CLDN1 showed a higher difference between primary malignant tumors and 
primary non-malignant tumors in terms of RNA levels.  
As we can see in Figure 49A, during the tumor malignancy, the CLDN4 up-
regulate tendency was reported in untreated patients (Figure 70A). However, 
these results were not completely conclusive, due the differences found were not 
significant. In the other hand, the up-regulation of CLDN1 was positive during 
tumor malignancy steps in PanNETs clinical data. As soon, was verified an 
increase CLDN1 expression in primary malignant tumors and metastasis in 
relation to primary non-malignant tumors (Figure 70B), thus, hinting a role for this 
protein as a tumor progression driver. Therefore, the clinical results demonstrated 
that our candidates seem might be acting together to maintain the collective 
invasion and, consequently, the tumor malignancy in PanNETs.   





Figure 70. Different steps of tumor malignancy in patients were associated with an increase of 
claudin1/4 RNA expression levels in clinical samples. PanNETs were grouped according to tumor 
malignancy steps. (A)  CLDN4 RNA levels from patients samples of non-malignant tumors (n=26), 
primary malignant tumors (n=31) and metastasis (n=7). Error bars represent S.D. (B) CLDN1 RNA 
levels from patients samples of non-malignant tumors (n=26), primary malignant tumors (n=31) and 
metastasis (n=7). Differences were statistically significant by Mann-Whitney test, being p=0.0010 in 
non-malignant tumors primary versus malignant tumors and p=0.0047 in non-malignant tumors primary 
versus metastasis.  
The gradual increases of CLDN4 and CLDN1 correlating with malignization, 
thus, suggesting the importance of these barrier-claudins to maintain the collective 
invasive Behaviour in PanNETs. Therefore, these molecules might be applied in 
the future as a prognostic biomarker to PanNETs tumor malignancy, as well as, a 



























Initially, angiogenesis inhibitors used for cancer treatment seemed to have 
many advantages over established drugs. Being that anti-angiogenic therapies 
target endothelial cells genetically, it was believed that these drugs would be 
completely effective and would not present tumor resistance. Over time, it has 
been realised that, even though endothelial cells are not transformed, this does 
not assure efficiency and absence of resistance to these drugs. Using the RIP1-
Tag2 model, it has been shown that after 4 weeks of treatment with DC101 (anti-
VEGFR2 monoclonal antibody), resistance to therapy was induced within the 
tumor. Thus, after initial efficacy in terms of tumor volume reduction, it was found 
that DC101 in the long-term induced a reestablishment of the tumor vasculature 
culminating in tumor regrowth (Casanovas et al. 2005). 
Later, in addition to adaptive tumor resistance being verified after 
VEGF/VEGFR2 inhibition, an increased invasiveness and metastatic capacity in 
RIP1-Tag2 tumors has also been observed. This invasion was also associated 
with high intratumoral hypoxia levels (Pàez-ribes et al. 2010). Molecularly, this 
invasive phenotype was shown to be related to the maintenance of proteins 
responsible for cell adhesion, seeming to favour a collective cell invasion mode. 
However, collective invasion in PanNETs has not been previously described, 
neither their relationship with anti-angiogenic treatment. In this way, the main 
objective of this thesis was to functionally validate the collective cancer cell 
movement in PanNETs before and after anti-angiogenic therapies using a 
translational approach: first in cell/spheroid models ‘in vitro’, followed by validation 
in the RIP1-Tag2 model of tumor invasion, and, finally, to confirm these findings 
in the clinical setting with samples of PanNETs. 
1. Morphological collective invasion characterization 
Most carcinomas may invade as cohesive multicellular groups through a 
process known as “collective invasion”. Alternatively, tumor cells can invade 
individually by two different processes: the protease-, and integrin-dependent 
“mesenchymal invasion” program or the protease-, integrin-independent 
“amoeboid invasion” program (Valastyan & Weinberg 2011). Despite the fact that 
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not all molecular determinants of each migration mode are completely understood, 
some key parameters have been identified as “checkpoints” to classify a given 
migration type (Peter Friedl and Wolf 2010). As an example, to confirm 
morphologically whether RIP1-Tag2 tumors locally invade in a collective manner, 
we used a methodology recommended by Friedl and colleagues in which he 
described the use of histological analysis of tumors in vivo to determine whether 
invasive cells are cohesive and maintain their cell-cell unions during invasion. All 
of these concepts were confirmed both in control tumors and in anti-angiogenic 
treated tumors. Thus, we concluded that RIP1-Tag2 tumors invade collectively 
whether treated or untreated with angiogenesis inhibition therapy, however it 
remained unclear whether this occurred through the same molecules (Peter Friedl 
et al. 2012). 
In addition, collective invasion is determined in vitro by a 3D ECM spheroid 
invasion method, that is, using multicellular aggregates that are seeded into 3D 
ECM (collagen I, Matrigel® or others) favouring radial invasion of multicellular 
strands. Strand size and shape and cell–cell adhesion junction immunostaining 
may determine differences between individual and collective invasion. The vertical 
penetration depth and the number of invasive strands are used to determine 
collective invasion capacity per spheroid (Peter Friedl et al. 2012). In order to 
follow this methodology, we developed spheroids from TC4 cells of RIP1-Tag2 
tumors and seeded them in three-dimensional conditions. As indicated in the 
literature, we morphologically verified the cluster of cells through DAPI staining, 
and the number of multicellular strands informed us about the level of invasion. 
Finally, the immunostaining pattern of CDH1 and CTNNB1 at the 3D level 
confirmed the maintenance of adhesion proteins in multicellular invasive strands. 
Importantly, this methodology has several limitations, the most important of which 
is the difficulty of antibody penetration into the 3D structure of Matrigel®. To 
answer this question, we extended the permeabilization and primary antibody 
incubation steps. Thus, the primary antibody incubation was applied for 2 nights, 
and the permeability solution was applied not only during permeabilization but also 
during blocking and antibody incubation steps. 




To set up the 3D technique and verify different parameters of culture, many 
3D invasion assay using spheroids TC4 were performed. During this step, the 
existence of two populations of TC4 spheroids, which differed substantially in 
terms of invasion capacity, was noted; these two subpopulations were deemed 
“high” and “low” TC4 spheroids. One possible explanation for this event is that 
the separation of TC4 spheroids in small plates for their growth at high 
confluence in in vitro culture may have favoured an expansion of certain high or 
low phenotype within each group. These two spheroid subpopulations are 
probably derived from the intratumoral heterogeneity observed in primary tumors. 
As we know, genomics research has revealed a substantial intratumor molecular 
heterogeneity that may evolve over the course of disease and exposure to 
treatment (Yap et al., 2012). Specifically, the tumor heterogeneity observed in 
NETs represents a very low mutation rate compared to other malignancies, though 
the engagement of epigenetic changes in driving NET evolution is emerging, 
mainly in genes that encode for proteins directly involved in chromatin remodelling 
(Di Domenico et al. 2017). An analysis using the RIP1-Tag2 model and human 
PanNET revealed that mutations in chromatin remodeling genes were enriched in 
intermediary and more metastatic tumors (Sadanandam et al. 2015).  Based on 
these data, we suspect that the heterogeneity observed in the two subpopulations 
of TC4 spheroids may be of epigenetic origin. However, high and low 
subpopulations still need to be better defined and clarified by both approaches, 
genetically and epigenetically. Thus, in this thesis these subpopulations were used 
only as a preliminary tool for screening possible collective invasion markers in 
vitro. 
2. Molecular collective invasion characterization 
Several authors agree that CDH1 is the protein most differentially 
expressed in cell tumors that invade collectively. The importance of this marker is 
even higher, given that its down regulation is necessary to characterize a full EMT 
(Lehembre et al. 2008; Peter Friedl et al. 2012; Mayor and Roberto 2012; 
Valastyan & Weinberg 2011; Peter Friedl and Mayor 2017). Specifically, via 
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CDH1, invasive cell clusters maintain their strong and stable cell adhesion, as well 
as their apicobasal polarity (Peter Friedl and Mayor 2017). Hence, CDH1 is 
considered a differential signal between collective and individual invasion in most 
cases.  
RIP1-Tag2 tumors express CDH1 at distinct levels and this well-known 
marker has been confirmed in untreated tumors, with expression correlated to 
tumoral invasion capacity. However, in tumors after anti-angiogenic treatment this 
mechanism is not clear. Unexpectedly, aggressive tumors, when treated with 
sunitinib, did not show a significant increase in CDH1 expression, suggesting that 
another mechanism may also be involved in the invasive increase after anti-
angiogenic treatment. These results corroborate that which has been observed in 
TC4 model, that in untreated conditions TC4 cells and spheroids showed an 
increase of CDH1 expression, which was correlated with a greater invasion 
capacity in 2D and 3D models. 
Previous evidence suggests that the invasive phenotype of RIP1-Tag2 
tumors does not involve a classical EMT. Chun and Hanahan described no 
detectable expression differences of EMT transcription factors in non-invasive IT 
and highly invasive IC2. In addition, N-cadherin, one prominent marker of EMT, is 
not obviously different between IT and IC2 lesions (Chun and Hanahan 2010). On 
the other hand, Lehembre and colleagues verified that the loss of E-cadherin 
levels induces upregulated expression of the NCAM gene, increasing integrin-
dependent mesenchymal cell migration and invasion (Lehembre et al. 2008). 
3.  Collective invasion candidates 
The claudin family was the most interesting group of genes obtained from 
the GSEA analysis data, for which RNA levels from untreated versus sunitinib 
treated RIP1-Tag2 tumors were compared. There are thought to be around 26 
human claudins with a physiological role (Günzel and Yu 2013). Some of them 
were described to be altered in several cancers (Osanai et al. 2017). In RIP1-Tag2 
tumors, barrier function claudins were associated with a more invasive phenotype 




in treated tumors. Among them, CLDN4 was the most highly expressed gene in 
sunitinib treated tumors compared to non-treated. In a recent review, data from 
different sources were grouped according to primary tumor organ of origin and the 
altered expression of different claudins. In the majority of cancer types CLDN4 
was found to be increased, such as breast, esophagus, stomach, large intestine, 
biliary tract, pancreas, bladder, kidney, prostate and ovary uterine corpus. 
However, in tumors from breast, stomach, large intestine, liver, bladder and 
uterine cervix, CLDN4 expression was found to be decreased (Osanai et al. 2017).  
A strong increase of CLDN4 expression was found after sunitinib and 
DC101 treatment, and this overexpression was also associated with a higher 
invasiveness in sunitinib treated samples. All of our findings led us to suggest that 
an increase in the barrier of cell-cell adhesions formed by CLDN4 might represent 
a crucial factor in contributing to local invasion. Furthermore, contrastingly from 
the CDH1 results, the differential CLDN4 expression between control and treated 
tumors was highly significant, showing that the collective invasion observed before 
and after anti-angiogenic treatment seems to be driven by the same molecules. 
To translate the CLDN4 results to TC4 cells and spheroids in vitro, we 
used 2D and 3D models. Surprisingly, we observed an absence of CLDN4 at the 
RNA and protein level in all models analysed, and further, every attempt to induce 
CLDN4 in vitro failed. Many cancer cell lines express CLDN4 in vitro, such as 
SKOV3 (ovarian), MCF-7 (breast), HEC-1A (endometrial) and PANC-1 (pancreas) 
(Cuevas et al. 2015; Nichols, Ashfaq, and Iacobuzio-Donahue 2004; Michl et al. 
2001; Casanovas et al. 2005; Hicks et al. 2016). Thus, the absence of CLDN4 in 
cell lines certainly is not an overall problem with different cell types. In fact, even 
though TC4 cells were derived from the RIP1-Tag2 tumor, we are not aware 
about the CLDN4 expression level specifically in this tumor. To verify whether the 
lack of CLDN4 was due to the non-expression of this protein by the tumor of origin, 
or whether there was loss of expression when these tumors were passed to the in 
vitro system, we compared different primary cells from different RIP1-Tag2 
tumors. Nevertheless, once more, we did not find protein levels of CLDN4 in any 
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of the three TC primary lines analysed. Indeed, these differences may be 
observed as a result of a true divergence between in vitro culture and the in vivo 
scenario.  This phenomenon is similar to that shown in other studies in the 
literature that demonstrate tumor subtypes which are not fully molecularly 
represented into cell lines (Goodspeed et al. 2016), such as in lung cells when12 
of 30 cancer cell lines were found to have distinct EGFR mutations within the same 
cultures (Nagai et al., 2005). This effect could be a consequence of biological 
mechanisms of heterogeneity within primary tumors, which may be operational in 
cell line models (Goodspeed et al. 2016). 
On the other hand, gene expression differences between primary 
xenografts of human small–cell lung cancer, cell lines derived from these tumors 
and secondary xenograft tumors from these cells have been investigated. As a 
result, gene expression differences between primary xenografts and monolayer 
culturing of the cell lines were identified, indicating genomic alterations between 
the two model systems. In the secondary xenograft, these genes remained 
differentially expressed, indicating that stable changes had occurred in in vitro 
culture (Daniel et al. 2009). 
In vivo cells primarily exist embedded within a complex and information-rich 
environment that contains multiple ECM components, mixed cell populations that 
interact heterotypically and a medley of cell-secreted factors. Many cell types, 
when isolated from tissues and placed into cell culture, become progressively 
flatter, divide aberrantly and lose part of their phenotype. Interestingly, some of 
these cell types may regain their physiological form and function when embedded 
in a three-dimensional (3D) in vitro culture environment (Baker and Chen 2012; 
Riffle and Hegde 2017; Goodspeed et al. 2016). Since our 3D model could not 
regain CLDN4 expression and among four TC cell lines analysed, none of them 
showed CLDN4 protein levels, a potential explanation for this observed 
phenomenon is that a switch between in vitro and in vivo models occurs among 
claudins. Under this hypothesis, another claudin family component would play the 
role of CLDN4 in TC4 cells. 




Through screening of barrier-forming claudins in βTC4 cells, the current 
study demonstrated an association between CLDN1 and invasion capacity in high 
βTC4 cells. Briefly, a molecular switch between barrier CLDN1/4 in our in vivo and 
in vitro model has been described, in which both claudins are more expressed in 
accordance with the greater tumor invasiveness capacity. Importantly, CLDN1 
acts only in the βTC4 in vitro model and CLDN4 only in the RIP-Tag2 in vivo model. 
Several reports have shown that CLDN4 and CLDN1 expression tends to either 
coincide, or not, in different tumor types such as breast, colorectal and gastric 
tumors (Hahn-Strömberg et al. 2017; Kwon 2013). However, the deeper 
relationship between these two proteins is still not well understood.  Taking into 
account that both CLDN1/4 increase transepithelial resistance and, that, 
overexpression of these claudins affects the same sealing function in distinct 
models, the key point here is not a specific member of the claudins but the barrier 
function as a whole. 
In order to discuss the association of CLDN1/4 in PanNETs patient 
samples, we performed a correlation analysis between CLDN1/4 and their adapter 
proteins based on RNA levels. Patient samples showed a significant correlation 
between CLDN1 and CLDN4 with TPJ2 (ZO2) protein (Figure 71A-B).  
Furthermore, CLDN4 and CLDN1 demonstrated a high correlated expression, 
thus, when one of the two proteins was more expressed the other protein followed 
the same pattern (Figure 71C). This information further corroborates barrier 
function from claudins as a relevant factor in this context, independently if whether 










Figure 71.  GEO data base demonstrated a correlation between CLDN1/4 and ZO2 in patients. 
Patient RNA level groups analysed were: normal pancreas islet (n=4), non-functional PNET (n=62), 
insulinoma (n=17) and metastasis (n=7). Spearman correlations were used to assess associations 
between continuous variables. Significance was determined by P value. (A) TPJ2 and CLDN1 
correlation; p=0.0239. (B) TJP2 and CLDN4 correlation; p<0.0001. (C) CLDN1 and CLDN4 correlation; 
p<0.0001. 
As previously discussed in this section, molecular expression alterations 
can be led by extracellular matrix presence in in vitro models, since the three-
dimensional environment provides tumor in vivo characteristics that are not 
present in traditional 2D models. In our results, low invasive βTC4 cell and 
spheroids in the 2D model showed irrelevant CLDN1 and CDH1 levels. When in 
the 3D microenvironment, βTC4 spheroids increase considerably the presence of 
CLDN1, but not CDH1.  These findings suggest that low βTC4 spheroids, with 
almost no CDH1 protein level, probably are able to invade collectively by the 
recruitment of CLDN1. Despite low levels, low βTC4 spheroids show a 1.5 strands 
per spheroid average. This rate represents significant invasion level considering 




the difficulty entailed in collective invasion through Matrigel® or in more complex 
3D environments. 
4. CLDN1 in vitro modulation 
The increase of hypoxic level in hyperinvasive tumors and metastatic 
lesions in the RIP1-Tag2 mouse model treated with anti-VEGFR2 and sunitinib 
have been well documented (Pàez-ribes et al. 2010). In this way, with a goal to 
translate in vivo molecular CLDN modulation to in vitro models, we used 10% 
hypoxia in combination with a lack of nutrients to mimic the anti-angiogenic 
therapy. We were able to verify increased CLDN1 protein level after the treatment, 
and consequently increased invasive capacity of βTC4 cells and spheroids. 
However, when we applied this methodology to verify this effect for the CLDN4 
molecule, as expected, we did not report any response in relation to CLDN4 
expression, which was understandable given that these cells do not express 
CLDN4 under control conditions. 
Following our objective, we continued investigating possible manners of 
modulating CLDN1 functions.  Internalization of TJ proteins from the plasma 
membrane is a crucial mechanism of regulating TJ plasticity and function in both 
epithelial and endothelial barrier tissues. When internalized, TJ proteins enter 
complex vesicular machinery, where further trafficking is directly dependent on the 
downstream signaling pathways that regulate the sorting and destiny of TJ 
proteins, as well as on cell and barrier responses (Stamatovic et al. 2017).  There 
is distinct internalization among individual tight junction proteins; CLDN1 
specifically is constantly endocytosed and recycled back to the plasma membrane 
in a range of epithelial cell lines (Gehne et al. 2017).   
Recent studies show that the constitutive recycling of CLDN1 is dependent 
upon Endosomal Sorting Complex Required for Transport (ESCRT) (Cai et al. 
2013). In this membrane trafficking protein, sorting of some proteins through cargo 
selection into mutivesicular bodies (MVB) is required (Jin, Lang, and Weisman 
2016). For protein sorting to be effective, PI(3,5)P2 action is necessary, which, in 
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turn, is a product of PI(3)P phosphorylation by the PIKfyve enzyme (Cai et al. 
2013). Thus, PIKfyve inhibition treatment causes non-conversion of PI(3)P into 
PI(3,5)P2, stopping the separation of proteins into mutivesicular bodies and 
preventing the ESCRT machinery from recycling CLDN1, and as a consequence, 
accumulating this protein intracellularly into vesicles.  
Dukes and colleagues demonstrated that PIKfyve inhibitor (YM201636) 
treatment is able to inhibit the endocytic CLDN1, providing intracellular 
accumulation and blocking its function in the membrane (Dukes, Whitley, and 
Chalmers 2012). Our in vitro data using 2D and 3D models showed that 
YM201636 inhibits tumor invasion by 3D invasion and Transwell® assay without 
affecting cellular phenotype and viability, suggesting a functional role of CLDN1 in 
βTC4 collective invasion. Corroborating our findings, several tumor types have 
demonstrated CLDN1 upregulation in invasive tumors, such as human samples 
from endometrial cancer and oral squamous carcinoma cells (Babkair et al. 2016; 
Shimada et al. 2017). Specifically, was related the increased collective migration 
and invasion by CLDN1 overexpression during collective movement in epithelial 
cells (Fortier, Asselin, and Cadrin 2013). Although there is some suspicion in 
relation to CLDN1 function and its effect in collective invasion, this is the first time 
that these results are described in PanNETs tumors. 
Since PIKfyve enzyme has also been linked to insulin-stimulated 
translocation of the glucose transporter GLUT4, replication of salmonella and 
regulation of glutamate transporters, other proteins could be affected besides 
CLDN1 during PIKfyve inhibition by YM201636 (Dukes, Whitley, and Chalmers 
2012). A future experiment that will provide clarity with regards to this inhibitor and 
will confirm the role of CLDN1 in collective invasion, will be the genetic silencing 
of CLDN1 through shRNA. For this, we will transfect TRC Lentiviral Mouse Cldn1 
shRNA system (Dharmacon) in high βTC4 cells.  Next, we will use high βTC4 
cells transitorily transfected with the shRNA to verify the invasion pattern after 
CLDN1 genetic silencing in our 2D and 3D models in vitro.  In addition, it would be 
interesting to use these cells to perform an in vivo study. In this way, shCLDN1 




cells and shNS cells would be injected into the subcutaneous or renal capsule of 
athymic nude mice, where tumor cells would grow and generate a palpable tumor. 
To study the impact of CLDN1 genetic silencing after anti-angiogenic resistance, 
mice would first receive DC101 therapy. Animals would be sacrificed after 4 weeks 
of treatment and the tumor tissue would be analysed for invasion capacity and 
histology and, finally, molecular CLDN1 silencing would be confirmed. 
5. Clinical samples validation 
In order to translate from the preclinical RIP1-Tag2 model and BTC4 
spheroids to human PanNET patients, a clinical data set of PanNET patient 
samples was used. These data were selected specifically for analysis, as 
described in Results (section 5.1), due to high molecular and phenotypical 
resemblance between non-functional primary tumors and RIP1-Tag2 invasive 
tumors. In addition, to evaluate our collective invasion candidates in clinical data, 
the selected samples from PanNETs were grouped in three progression stages, 
primary non-malignant tumors, primary malignant tumors and metastasis 
(Sadanandam et al. 2015).  
Recently the research value of RIP1-Tag2 tumors for its cognate human 
cancer was evaluated, using a genomic comparison of tumors from both human 
and mice samples. For this, RIP1-Tag2 tumors were separated into two distinct 
subtypes: well-differentiated IT and poorly differentiated tumors associated with 
liver metastasis (MLP). Human PanNETs were independently split into these 
same two subtypes. As a result, MLP subtypes in human and mouse were similar 
to liver metastases, taking into account their transcriptome profiles and signature 
genes, coinciding with a non-functional signature. Therefore, this evaluation 
confirmed that the molecular mechanisms of PanNET tumors might be studied 
using the RIP1-Tag2 model as a surrogate for both human functional and non-
functional tumors (Sadanandam et al. 2015). On the other hand, there is also 
evidence for genetic and phenotypic heterogeneity in RIP1-Tag2 tumors, since a 
range of chromosomal aberrations have been observed (Hodgson et al. 2001). 
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Our results demonstrated that among barrier claudins the three most 
differentially expressed in malignant primary tumors in relation to non-malignant 
primary tumors were CLDN1, CLDN3 and CLDN4. Surprisingly, CLDN1 and 
CLDN4 are our collective candidates from preclinical studies, and in patient data 
they were also found to be highly expressed in malignant tumors in comparison to 
non-malignant tumors. Ultimately, we verified a significant up-regulation of CLDN1 
in accordance with the higher level of tumor malignancy in PanNETs clinical data. 
However, despite the tendency of CLDN4 to increase levels in more malignant 
lesions, these results were not significant. Thus, PanNET tumor results also 
suggest that barrier claudins perform a crucial role in collective invasion, involving 
specific claudin members CLDN1 or CLDN4, depending the context, but it is the 
barrier function as a whole that seems to be key in this process. Even though more 
comprehensive studies are surely necessary, our results suggest that barrier 
claudins, and specifically CLDN1 and CLDN4 in PanNETs, could in future be a 
useful prognostic biomarker for patients, and a possible second-line target to avoid 
tumor invasion after treatment resistance.  
6. Clinical relevance and future treatments 
As mentioned before, in most types of cancer CLDN4 is found to be 
increased, for example in breast, esophagus, stomach, large intestine, biliary tract, 
pancreas, bladder, kidney, prostate and ovary uterine corpus. On the other hand, 
in tumors from breast, stomach, large intestine, liver, bladder and uterine cervix, 
CLDN4 expression is found to be decreased (Osanai et al. 2017).  
Taking into account this group of tumors, the closest to PanNETs are 
pancreatic tumors. In patient pancreatic samples, strong CLDN4 expression was 
apparent in 99% of primary pancreatic ductal adenocarcinomas, and in 100% of 
metastatic pancreatic ductal adenocarcinomas in comparison to only 19% of 
normal pancreatic duct epithelium (Kojima, Kyuno, and Sawada 2012). Our 
findings in PanNETs are equivalent to those found in pancreatic tumors; we found 
a strong increase of CLDN4 after sunitinib and DC101 treatment, and this 




overexpression was also associated with a higher invasiveness in sunitinib treated 
samples. 
Regarding inhibition of claudins in patients, apilimod is a first-in-class 
PIKfyve kinase inhibitor, and this drug has demonstrated promising results in B-
cell non-Hodgkin lymphoma (B-NHL) and is undergoing a human phase I clinical 
trial (NCT02594384) estimated to be finalized in December of 2019. PIKfyve 
kinase was verified as a target for B-NHL and its inhibition by apilimod 
demonstrated powerful and selective antiproliferative and cytotoxic effects. 
Nonetheless, even though potent effects of apilimod have been demonstrated, this 
clinical trial was performed prior to the identification of its direct target, which has 
been described until now as the role of PIKfyve to control endolysosomal 
membrane traffic (Gayle et al. 2017).  
In this sense, PIKfyve kinase inhibitors could be also indicated in other 
cancer types such as PanNETs, focusing on CLDN1 inhibition, provided that the 
findings obtained in this thesis were confirmed in further preclinical studies.  In any 
case, the results of these clinical trials will enlighten as to the safety and tolerability 
of PIKfyve inhibitors, helping to determine side effects from this therapy regardless 
of the disease. 
7. Claudin binders as a novel strategy to treat cancer 
As detailed in the Introduction, claudin structurally has four transmembrane 
domains, of which two are extracellular loops. The first extracellular loop is the 
coreceptor required for entry of hepatitis C virus (HCV) and influences the 
paracellular charge selectivity, and the second extracellular loop is the receptor of 
Clostridium perfringens enterotoxin (CPE). CPE is the toxin with major virulence 
of C. perfringens. It has been described that claudin-3, -4, -6, -7, -8, and -14, but 
not claudin-1, -2, -5, and -10, are sensitive to CPE. A single CPE polypeptide is 
comprised of 319 amino acids, has a molecular weight of 35kDa and causes food 
poisoning in humans, in which it binds to its claudin receptor, then causes changes 
in membrane permeability via a complex formation on the plasma membrane, 
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followed by the induction of apoptosis (Kojima, Kyuno, and Sawada 2012). Recent 
data reported CLDN4 as crucial in tumor progression via proliferation, 
transformation, and metastasis (Liang et al. 2017). Additionally, CLDN4 protein is 
highly expressed in many kinds of malignant tumors, among them pancreatic, 
ovarian, gastric and prostate (English and Santin 2013; Liang et al. 2017; Kojima, 
Kyuno, and Sawada 2012; Romanov et al. 2014). 
In gastric cancer the cytotoxic effect of CPE was determined in vivo in 
xenograft mouse models, in which one group was treated with CPE and the other 
was not.  The CPE positive group significantly suppressed tumor growth and had 
reduced tumor volume in relation to untreated animals. However, these treated 
animals showed injection site skin necrosis and enteritis as a consequence of the 
treatment (Liang et al. 2017).  Some studies altered the structure of CPE to 
overcome systemic toxicity. In order to treat prostate cancer selectively with CPE 
enterotoxin, a modified protoxin was constructed with a flexible linker containing a 
PSA-specific protease cleavage site. Being that PSA is secreted and active only 
in prostate cancer cells, the cytotoxicity toward PSA-negative but CLDN4-
expressing cells was greatly reduced or eliminated (Romanov et al. 2014).  
Therefore, the use of CPE optimized with a focus on target gene therapy is 
one strategy that might be explored in all tumors that overexpress CLDN4 and 
other CPE-binding claudins. Given that invasive RIP1-Tag2 tumors were found to 
be associated with CLDN4 upregulation after the anti-angiogenic treatment, 
optimized CPE could be a relevant strategy to overcome collective invasion and 
reduce tumoral malignancy observed after therapy. 
Some authors have identified CLDN1 as essential for HCV entry. In detail, 
residues within the first extracellular loop of CLDN1, but not protein interaction 
motifs in intracellular domains, are crucial for HCV entry. In the development of 
antiviral drug antibodies, an antibody directed against an epitope inserted in the 
first extracellular loop of CLDN1 was able to block HCV infection (Fukasawa et al. 
2015). This binding site of CLDN1 has not yet been applied as an approach in the 




treatment of cancer but could be interesting to explore in the future to treat several 
cancer types that show a CLDN1 overexpression pattern (Hashimoto et al. 2017). 
Finally, to improve CLDN-targeted based therapies in future, it is crucial to 
define CLDN binders in detail. This information will be beneficial for developing 
the next generation of CLDN binders, including chemicals, peptides, and 
functional antibodies. Thus, determining the complex structures of different 
CLDNs and anti-CLDN antibodies will help in theoretical in silico drug design for 
CLDN-targeted drug development. The future of CLDN-targeted therapy seems to 
be promising, given that several groups are already determining and screening 
new types of CLDN binders, and clinical trials of anti-CLDN antibodies as 
antitumor reagents are ongoing (Hashimoto et al. 2017). 
Furthermore, the ease of bonding of claudins provided by coreceptors in 
their extracellular loops is part of a whole promising context that has been 
described in relation to Claudin binders. In the future, these strategies could be 
applied in PanNETs tumors, aiming to intervene in tumor progression steps. 
Overall, this thesis has shed light on the biology of collective invasion in 
PanNETs, and though more comprehensive studies are surely required, our 
results suggest that barrier claudins, and in specific CLDN1 and CLDN4 in 
PanNETs, could be a useful prognostic biomarker for patients in the future, and a 
















































1. Morphologically, the invasion of RIP1-Tag2 tumors is determined by 
collective cancer cell invasion, in which cancer cells invade in multicellular 
strands across acinar tissue and remain attached to a large tumor mass. 
2. We have successfully set up an in vitro three-dimensional tumor model 
using spheroids from βTC4 cells which mimic collective invasion effects 
before and after anti-angiogenic treatment. 
3. βTC4 spheroids in a three-dimensional model have a collective invasion 
behaviour, whereby spheroids invade in multicellular strands while 
maintaining epithelial markers CDH1 and CTNNB1 along their protusions. 
4. The invasion mechanism in RIP1-Tag2 untreated tumors is associated with 
CDH1 function, but in RIP1-Tag2 tumors after anti-angiogenic treatment 
this relationship is not observed, suggesting that other players are 
important. 
5. CLDN4 protein seems to induce invasiveness before and after anti-
angiogenic therapy in RIP1-Tag2 tumors, which is involved in barrier 
function stability and increased integrity adhesion between cells and is 
thereby associated with tumor collective invasiveness capacity. 
6. CLDN1 functional validations in βTC4 cells and spheroids demonstrated a 
direct implication of CLDN1 in cancer cell invasion in 2D and 3D models. 
7. In PanNETs patients, CLDN1 is strongly associated with tumor progression. 
8. This study suggests that barrier-forming claudins, and especially CLDN1, 
might be suitable tumor progression biomarkers for PanNETs tumors, as 
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